Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyBiologicalProcess	multi-pass transmembrane protein insertion into ER membrane	NOMO1 NOMO2 NOMO3	2.77e-05	9	145	3	GO:0160063
GeneOntologyBiologicalProcess	cellular response to caffeine	CACNA1S SELENON RYR1	5.39e-05	11	145	3	GO:0071313
GeneOntologyBiologicalProcess	calcium ion transport	CACNA1S TRPC5 DBI EFHB SELENON RYR1 AHNAK AGT ASPH TRPV3 DMD ATP2B2 ATP2B4	6.45e-05	509	145	13	GO:0006816
GeneOntologyBiologicalProcess	calcium ion transmembrane transport	CACNA1S TRPC5 DBI SELENON RYR1 AHNAK ASPH TRPV3 DMD ATP2B2 ATP2B4	1.06e-04	392	145	11	GO:0070588
GeneOntologyBiologicalProcess	cellular response to purine-containing compound	CACNA1S SELENON RYR1	1.17e-04	14	145	3	GO:0071415
GeneOntologyBiologicalProcess	glial cell development	ITGB4 ZEB2 PRX SIRT2 AGT LRP1 DMD	1.24e-04	157	145	7	GO:0021782
GeneOntologyBiologicalProcess	intracellular chemical homeostasis	CACNA1S COX19 HK2 ACO1 TRPC5 HKDC1 DBI SELENON RYR1 ARRB1 AGT ASPH LRP1 ALAS2 DMD ATP2B2 ATP2B4	1.27e-04	866	145	17	GO:0055082
GeneOntologyBiologicalProcess	positive regulation of DNA-templated DNA replication	ATRX INO80 CDK2	1.46e-04	15	145	3	GO:2000105
GeneOntologyBiologicalProcess	calcium ion transmembrane import into cytosol	CACNA1S DBI SELENON RYR1 ASPH TRPV3 DMD ATP2B4	1.53e-04	217	145	8	GO:0097553
GeneOntologyBiologicalProcess	membrane biogenesis	SELENON RFTN1 SIRT2 PTPRD NRXN2	1.64e-04	73	145	5	GO:0044091
GeneOntologyBiologicalProcess	chemical homeostasis	CACNA1S COX19 HK2 ACO1 TRPC5 HECTD4 HKDC1 APOB DBI SELENON RYR1 ABCB4 ARRB1 AGT ASPH LRP1 ALAS2 DMD ATP2B2 ATP2B4 UNC80	1.75e-04	1249	145	21	GO:0048878
GeneOntologyBiologicalProcess	neuron cell-cell adhesion	NRXN3 NRXN2 ASTN1	1.78e-04	16	145	3	GO:0007158
GeneOntologyCellularComponent	multi-pass translocon complex	NOMO1 NOMO2 NOMO3	2.77e-05	9	147	3	GO:0160064
GeneOntologyCellularComponent	ER membrane insertion complex	NOMO1 NOMO2 NOMO3	1.17e-04	14	147	3	GO:0072379
GeneOntologyCellularComponent	presynapse	DOC2A TRPC5 SLC35G2 DBI PDLIM5 SLC6A11 NRXN3 PTPRD NRXN2 PIK3C3 CADPS SLC6A5 SENP6 RIMS1 DMD ATP2B2 ATP2B4	1.69e-04	886	147	17	GO:0098793
GeneOntologyCellularComponent	contractile muscle fiber	CACNA1S MYL2 DBI PDLIM5 RYR1 AHNAK MMP2 DMD ATP2B4	2.18e-04	290	147	9	GO:0043292
GeneOntologyCellularComponent	presynaptic active zone membrane	NRXN3 NRXN2 RIMS1 ATP2B2 ATP2B4	2.24e-04	78	147	5	GO:0048787
GeneOntologyCellularComponent	extrinsic component of membrane	DOC2A RYR1 JAK1 PIK3C2G PIK3C3 CADPS RIMS1 CDH18	2.28e-04	230	147	8	GO:0019898
GeneOntologyCellularComponent	myofibril	CACNA1S MYL2 PDLIM5 RYR1 AHNAK MMP2 DMD ATP2B4	7.13e-04	273	147	8	GO:0030016
GeneOntologyCellularComponent	mCRD-mediated mRNA stability complex	PABPC1 PABPC3	7.23e-04	6	147	2	GO:0106002
GeneOntologyCellularComponent	heterochromatin	ATRX IKZF1 SIRT2 TNKS1BP1 KDM4B	7.40e-04	101	147	5	GO:0000792
GeneOntologyCellularComponent	presynaptic membrane	SLC6A11 NRXN3 PTPRD NRXN2 SLC6A5 RIMS1 ATP2B2 ATP2B4	7.83e-04	277	147	8	GO:0042734
GeneOntologyCellularComponent	synaptic membrane	ITGB4 SLC6A11 ARRB1 NRXN3 PTPRD NRXN2 SLC6A5 LRP1 RIMS1 DMD ATP2B2 ATP2B4	8.71e-04	583	147	12	GO:0097060
GeneOntologyCellularComponent	GABA-ergic synapse	SLC6A11 NRXN3 PIK3C3 RIMS1 DMD ATP2B2	1.08e-03	164	147	6	GO:0098982
HumanPheno	Abnormal blood carbon dioxide level	CACNA1S MYL2 SELENON RYR1	4.15e-06	14	43	4	HP:0500164
HumanPheno	Hypercapnia	CACNA1S MYL2 SELENON RYR1	4.15e-06	14	43	4	HP:0012416
Domain	DUF2012	NOMO1 NOMO2 NOMO3	1.82e-06	4	145	3	PF09430
Domain	DUF2012	NOMO1 NOMO2 NOMO3	1.82e-06	4	145	3	IPR019008
Domain	Ribosomal_S6_kinase_II	RPS6KA5 RPS6KA2 RPS6KA3	9.01e-06	6	145	3	IPR016239
Domain	Carb-bd-like_fold	NOMO1 NOMO2 NOMO3	2.49e-05	8	145	3	IPR013784
Domain	CarboxyPept_regulatory_dom	NOMO1 NOMO2 NOMO3	1.24e-04	13	145	3	IPR014766
Domain	-	NOMO1 NOMO2 NOMO3	1.24e-04	13	145	3	2.60.40.1120
Domain	TPR-contain_dom	RANBP2 ASPH VPS13A PDCD11 ZC3H7B DNAJC3 EDRF1	1.72e-04	150	145	7	IPR013026
Domain	-	RANBP2 CFAP54 ASPH PDCD11 IFT122 ZC3H7B DNAJC3 EDRF1	2.16e-04	207	145	8	1.25.40.10
Domain	CarboxyPept-like_regulatory	NOMO1 NOMO2 NOMO3	2.88e-04	17	145	3	IPR008969
Domain	ATP_Ca_trans_C	ATP2B2 ATP2B4	3.56e-04	4	145	2	IPR022141
Domain	ATP_Ca_trans_C	ATP2B2 ATP2B4	3.56e-04	4	145	2	PF12424
Domain	P-type_ATPase_IIB	ATP2B2 ATP2B4	3.56e-04	4	145	2	IPR006408
Domain	TPR-like_helical_dom	RANBP2 CFAP54 ASPH PDCD11 IFT122 ZC3H7B DNAJC3 EDRF1	4.79e-04	233	145	8	IPR011990
Domain	PolyA	PABPC1 PABPC3	5.89e-04	5	145	2	SM00517
Domain	Hexokinase_2	HK2 HKDC1	5.89e-04	5	145	2	PF03727
Domain	-	PABPC1 PABPC3	5.89e-04	5	145	2	1.10.1900.10
Domain	PABP	PABPC1 PABPC3	5.89e-04	5	145	2	PF00658
Domain	PABP_1234	PABPC1 PABPC3	5.89e-04	5	145	2	IPR006515
Domain	Hexokinase_BS	HK2 HKDC1	5.89e-04	5	145	2	IPR019807
Domain	Hexokinase_C	HK2 HKDC1	5.89e-04	5	145	2	IPR022673
Domain	Hexokinase_N	HK2 HKDC1	5.89e-04	5	145	2	IPR022672
Domain	Hexokinase_1	HK2 HKDC1	5.89e-04	5	145	2	PF00349
Domain	PABC	PABPC1 PABPC3	5.89e-04	5	145	2	PS51309
Domain	HEXOKINASE_2	HK2 HKDC1	5.89e-04	5	145	2	PS51748
Domain	PABP_HYD	PABPC1 PABPC3	5.89e-04	5	145	2	IPR002004
Domain	HEXOKINASE_1	HK2 HKDC1	5.89e-04	5	145	2	PS00378
Domain	C2	DOC2A PIK3C2G PIK3C3 CADPS RIMS1 RASAL1	7.05e-04	137	145	6	SM00239
Domain	Hexokinase	HK2 HKDC1	8.80e-04	6	145	2	IPR001312
Domain	Syndecan	NRXN3 NRXN2	1.23e-03	7	145	2	PF01034
Domain	Syndecan/Neurexin_dom	NRXN3 NRXN2	1.23e-03	7	145	2	IPR027789
Domain	Helicase_C	ERCC3 ATRX CHD1L INO80 DDX46	1.48e-03	107	145	5	PF00271
Domain	HELICc	ERCC3 ATRX CHD1L INO80 DDX46	1.48e-03	107	145	5	SM00490
Domain	Helicase_C	ERCC3 ATRX CHD1L INO80 DDX46	1.55e-03	108	145	5	IPR001650
Domain	HELICASE_CTER	ERCC3 ATRX CHD1L INO80 DDX46	1.61e-03	109	145	5	PS51194
Domain	HELICASE_ATP_BIND_1	ERCC3 ATRX CHD1L INO80 DDX46	1.61e-03	109	145	5	PS51192
Domain	DEXDc	ERCC3 ATRX CHD1L INO80 DDX46	1.61e-03	109	145	5	SM00487
Domain	PI3K_C2	PIK3C2G PIK3C3	1.63e-03	8	145	2	SM00142
Domain	PI3K_C2_dom	PIK3C2G PIK3C3	1.63e-03	8	145	2	IPR002420
Domain	PI3K_C2	PIK3C2G PIK3C3	1.63e-03	8	145	2	PF00792
Domain	PI3K_C2	PIK3C2G PIK3C3	1.63e-03	8	145	2	PS51547
Domain	Helicase_ATP-bd	ERCC3 ATRX CHD1L INO80 DDX46	1.68e-03	110	145	5	IPR014001
Domain	C2_dom	DOC2A PIK3C2G PIK3C3 CADPS RIMS1 RASAL1	1.78e-03	164	145	6	IPR000008
Domain	EF-hand-dom_pair	CACNA1S MYL2 EFHB SELENON RYR1 S100P DMD MYL10	1.83e-03	287	145	8	IPR011992
Domain	TPR_REGION	RANBP2 ASPH VPS13A ZC3H7B DNAJC3 EDRF1	1.84e-03	165	145	6	PS50293
Domain	TPR	RANBP2 ASPH VPS13A ZC3H7B DNAJC3 EDRF1	1.84e-03	165	145	6	PS50005
Domain	SNF2_N	ATRX CHD1L INO80	1.93e-03	32	145	3	IPR000330
Domain	SNF2_N	ATRX CHD1L INO80	1.93e-03	32	145	3	PF00176
Domain	PI3Ka	PIK3C2G PIK3C3	2.08e-03	9	145	2	PF00613
Domain	PI3Ka	PIK3C2G PIK3C3	2.08e-03	9	145	2	SM00145
Domain	-	PIK3C2G PIK3C3	2.08e-03	9	145	2	1.25.40.70
Domain	PI_Kinase	PIK3C2G PIK3C3	2.59e-03	10	145	2	IPR015433
Domain	Macro_dom	CHD1L PARP9	2.59e-03	10	145	2	IPR002589
Domain	PInositide-3_kin_accessory_dom	PIK3C2G PIK3C3	2.59e-03	10	145	2	IPR001263
Domain	MACRO	CHD1L PARP9	2.59e-03	10	145	2	PS51154
Domain	PIK_HELICAL	PIK3C2G PIK3C3	2.59e-03	10	145	2	PS51545
Domain	Clathrin_mu	AP1M2 AP5M1	2.59e-03	10	145	2	IPR001392
Domain	Pkinase_C	RPS6KA5 RPS6KA2 RPS6KA3	2.94e-03	37	145	3	IPR017892
Domain	Adap_comp_sub	AP1M2 AP5M1	3.14e-03	11	145	2	PF00928
Domain	Kinase-like_dom	ANKK1 RPS6KA5 RPS6KA2 RPS6KA3 JAK1 PIK3C2G PIK3C3 TESK2 BUB1 DMD CDK2	3.40e-03	542	145	11	IPR011009
Domain	C2	DOC2A PIK3C2G CADPS RIMS1 RASAL1	3.58e-03	131	145	5	PF00168
Domain	Pkinase_C	RPS6KA5 RPS6KA2 RPS6KA3	4.22e-03	42	145	3	PF00433
Domain	MHD	AP1M2 AP5M1	4.41e-03	13	145	2	PS51072
Domain	MHD	AP1M2 AP5M1	4.41e-03	13	145	2	IPR028565
Domain	EF-hand_6	MYL2 MYL10	4.41e-03	13	145	2	PF13405
Domain	C2	DOC2A PIK3C2G CADPS RIMS1 RASAL1	5.04e-03	142	145	5	PS50004
Domain	Neurexin-like	NRXN3 NRXN2	5.12e-03	14	145	2	IPR003585
Domain	4.1m	NRXN3 NRXN2	5.12e-03	14	145	2	SM00294
Domain	PI3/4_kinase_CS	PIK3C2G PIK3C3	5.88e-03	15	145	2	IPR018936
Domain	-	DOC2A PIK3C2G PIK3C3 RIMS1 RASAL1	5.99e-03	148	145	5	2.60.40.150
Domain	-	PIK3C2G PIK3C3	6.69e-03	16	145	2	1.10.1070.11
Domain	ATPase_P-typ_TM_dom	ATP2B2 ATP2B4	6.69e-03	16	145	2	IPR023298
Domain	PI3Kc	PIK3C2G PIK3C3	6.69e-03	16	145	2	SM00146
Domain	-	ATP2B2 ATP2B4	6.69e-03	16	145	2	1.20.1110.10
Domain	Poly(ADP-ribose)pol_cat_dom	PARP6 PARP9	7.54e-03	17	145	2	IPR012317
Domain	PARP_CATALYTIC	PARP6 PARP9	7.54e-03	17	145	2	PS51059
Domain	ATPase_P-typ_cation-transptr_C	ATP2B2 ATP2B4	7.54e-03	17	145	2	IPR006068
Domain	Cation_ATPase_C	ATP2B2 ATP2B4	7.54e-03	17	145	2	PF00689
Domain	PARP	PARP6 PARP9	7.54e-03	17	145	2	PF00644
Domain	-	PARP6 PARP9	7.54e-03	17	145	2	3.90.228.10
Pathway	REACTOME_CREB_PHOSPHORYLATION	RPS6KA5 RPS6KA2 RPS6KA3	1.63e-05	7	111	3	M27096
Pathway	REACTOME_CREB_PHOSPHORYLATION	RPS6KA5 RPS6KA2 RPS6KA3	1.63e-05	7	111	3	MM14784
Pubmed	In-Depth In Vivo Crosslinking in Minutes by a Compact, Membrane-Permeable, and Alkynyl-Enrichable Crosslinker.	DOC2A KNTC1 PTBP3 STRN3 RANBP2 WBP11 ATRX FBF1 HKDC1 APOB PRPF8 KLF4 PABPC1 ZEB2 PRX ABCB4 RFTN1 ARRB1 NRXN3 PABPC3 AHNAK VPS13A IFT122 ALAS2 RIMS1 DMD PSPC1 ATP2B2 DNAJC3 BAHCC1	5.53e-13	1442	149	30	35575683
Pubmed	Recurrent NOMO1 Gene Deletion Is a Potential Clinical Marker in Early-Onset Colorectal Cancer and Is Involved in the Regulation of Cell Migration.	NOMO1 NOMO2 NOMO3	7.71e-08	3	149	3	36011023
Pubmed	Silencing of nodal modulator 1 inhibits the differentiation of P19 cells into cardiomyocytes.	NOMO1 NOMO2 NOMO3	7.71e-08	3	149	3	25576386
Pubmed	Establishment of a conditional Nomo1 mouse model by CRISPR/Cas9 technology.	NOMO1 NOMO2 NOMO3	3.07e-07	4	149	3	31833031
Pubmed	A locus for autosomal recessive pseudoxanthoma elasticum, with penetrance of vascular symptoms in carriers, maps to chromosome 16p13.1.	NOMO1 NOMO2 NOMO3	3.07e-07	4	149	3	9267806
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	DCHS2 WBP11 ATRX ACO1 TAF1C HECTD4 ADNP2 PRPF8 ZEB2 PDLIM5 JAK1 ARRB1 PTPRD NOMO2 CADPS HECTD2 LRP1 SENP6 ASTN1 IFT122	6.60e-07	1285	149	20	35914814
Pubmed	Identification and functional characterization of transcriptional activators in human cells.	KNTC1 ADNP2 ZEB2 ZNF518A KDM2A IFT122 MGA DNAJC3 KDM4B CDK2 BAHCC1	1.29e-06	398	149	11	35016035
Pubmed	Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.	RPS6KA3 AP1M2 APOB ITGB4 PTPRD AIFM1 AHNAK VPS13A ATP2B4	1.75e-06	256	149	9	24189400
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	STRN3 RANBP2 ERCC3 ATRX TAF1C SRP54 INO80 KLF4 EMSY NOMO1 RFTN1 DDX46 ARRB1 RPL7L1 ASPH PDCD11 CEP131 ZC3H7B PSPC1 EDRF1 MAN1B1	1.78e-06	1497	149	21	31527615
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	PTBP3 WBP11 ERCC3 RPS6KA3 TAF1C SRP54 APOB CHD1L PRPF8 PABPC1 PDLIM5 S100P DDX46 AIFM1 AHNAK ASPH PDCD11 CEP131 PSPC1 ATP2B4	1.78e-06	1371	149	20	36244648
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	FBF1 HECTD4 INO80 DDX46 ATG4B NRXN3 NRXN2 SENP6 PDCD11 TNKS1BP1 ZC3H7B KDM4B	3.26e-06	529	149	12	14621295
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	STRN3 RANBP2 WBP11 RPS6KA2 HECTD4 PABPC1 ZEB2 EMSY PTPRD PABPC3 LRP1 CEP131 RIMS1 MGA ATP2B4 RASAL1	4.16e-06	963	149	16	28671696
Pubmed	Combinatorial expression of neurexins and LAR-type phosphotyrosine phosphatase receptors instructs assembly of a cerebellar circuit.	NRXN3 PTPRD NRXN2	4.25e-06	8	149	3	37591863
Pubmed	Over-expression of Grhl2 causes spina bifida in the Axial defects mutant mouse.	GRHL2 PABPC1 PABPC3	4.25e-06	8	149	3	21262862
Pubmed	Nicalin and its binding partner Nomo are novel Nodal signaling antagonists.	NOMO1 NOMO2 NOMO3	4.25e-06	8	149	3	15257293
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	RANBP2 ERCC3 HK2 TAF1C ADNP2 SRP54 CHD1L RRM2 PRPF8 PABPC1 SMG8 ATG4B RPL7L1 AIFM1 AHNAK ASPH PDCD11 KDM2A MGA	5.71e-06	1353	149	19	29467282
Pubmed	Substrate-driven assembly of a translocon for multipass membrane proteins.	NOMO1 NOMO2 NOMO3	6.35e-06	9	149	3	36261522
Pubmed	Increased muscle stress-sensitivity induced by selenoprotein N inactivation in mouse: a mammalian model for SEPN1-related myopathy.	CACNA1S SELENON RYR1	6.35e-06	9	149	3	21858002
Pubmed	Distinct transcriptomic changes in E14.5 mouse skeletal muscle lacking RYR1 or Cav1.1 converge at E18.5.	CACNA1S MYL2 KLF4 RYR1	7.07e-06	29	149	4	29543863
Pubmed	AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis.	CACNA1S RYR1 DMD	9.05e-06	10	149	3	18434328
Pubmed	An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance.	ZEB2 NOMO1 NOMO2 NOMO3	1.20e-05	33	149	4	30783098
Pubmed	An ER translocon for multi-pass membrane protein biogenesis.	NOMO1 NOMO2 NOMO3	1.24e-05	11	149	3	32820719
Pubmed	Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.	ENPP6 STRN3 FBXW10 HK2 RPS6KA5 RPS6KA2 RPS6KA3 LRP1 KDM2A MMP2 PSPC1 ATP2B4 CDK2	1.69e-05	730	149	13	34857952
Pubmed	Ca2+ influx through alpha1S DHPR may play a role in regulating Ca2+ release from RyR1 in skeletal muscle.	CACNA1S RYR1	1.82e-05	2	149	2	12954602
Pubmed	Identification of a Klf4-dependent upstream repressor region mediating transcriptional regulation of the myocardin gene in human smooth muscle cells.	KLF4 MYOCD	1.82e-05	2	149	2	24060351
Pubmed	Investigating the genetic susceptibility to exertional heat illness.	CACNA1S RYR1	1.82e-05	2	149	2	32054689
Pubmed	Effects of conformational peptide probe DP4 on bidirectional signaling between DHPR and RyR1 calcium channels in voltage-clamped skeletal muscle fibers.	CACNA1S RYR1	1.82e-05	2	149	2	21575570
Pubmed	Muscle CD31(-) CD45(-) side population cells promote muscle regeneration by stimulating proliferation and migration of myoblasts.	MMP2 DMD	1.82e-05	2	149	2	18669618
Pubmed	Multiple regions of RyR1 mediate functional and structural interactions with alpha(1S)-dihydropyridine receptors in skeletal muscle.	CACNA1S RYR1	1.82e-05	2	149	2	12496092
Pubmed	Clinical utility gene card for: malignant hyperthermia.	CACNA1S RYR1	1.82e-05	2	149	2	21248738
Pubmed	Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families.	CACNA1S RYR1	1.82e-05	2	149	2	24013571
Pubmed	Analysis of the entire ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding regions for variants associated with malignant hyperthermia in Australian families.	CACNA1S RYR1	1.82e-05	2	149	2	25735680
Pubmed	Functional expression of transgenic 1sDHPR channels in adult mammalian skeletal muscle fibres.	CACNA1S RYR1	1.82e-05	2	149	2	21262876
Pubmed	The promoter of the Poly(A) binding protein 2 (Pabp2) retroposon is derived from the 5'-untranslated region of the Pabp1 progenitor gene.	PABPC1 PABPC3	1.82e-05	2	149	2	10534404
Pubmed	Microdiversity of human-plasma-membrane calcium-pump isoform 2 generated by alternative RNA splicing in the N-terminal coding region.	ATP2B2 ATP2B4	1.82e-05	2	149	2	1313367
Pubmed	Increasing the number of diagnostic mutations in malignant hyperthermia.	CACNA1S RYR1	1.82e-05	2	149	2	19191329
Pubmed	Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.	CACNA1S RYR1	1.82e-05	2	149	2	9199552
Pubmed	Plasma membrane calcium pump (PMCA) isoform 4 is targeted to the apical membrane by the w-splice insert from PMCA2.	ATP2B2 ATP2B4	1.82e-05	2	149	2	22252018
Pubmed	β4 integrin marks interstitial myogenic progenitor cells in adult murine skeletal muscle.	ITGB4 DMD	1.82e-05	2	149	2	22205679
Pubmed	Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity.	KLF4 MYOCD	1.82e-05	2	149	2	25100730
Pubmed	Plasma membrane Ca²⁺-ATPases can shape the pattern of Ca²⁺ transients induced by store-operated Ca²⁺ entry.	ATP2B2 ATP2B4	1.82e-05	2	149	2	25690014
Pubmed	Nucleotide sequence of a mouse testis poly(A) binding protein cDNA.	PABPC1 PABPC3	1.82e-05	2	149	2	1630930
Pubmed	Four calcium signaling pathway-related genes were upregulated in microcystic adnexal carcinoma: transcriptome analysis and immunohistochemical validation.	CACNA1S RYR1	1.82e-05	2	149	2	35509066
Pubmed	Reciprocal regulation of integrin β4 and KLF4 promotes gliomagenesis through maintaining cancer stem cell traits.	KLF4 ITGB4	1.82e-05	2	149	2	30658712
Pubmed	Developmental expression of poly(A) binding protein mRNAs during spermatogenesis in the mouse.	PABPC1 PABPC3	1.82e-05	2	149	2	7893484
Pubmed	Characterization of two cytoplasmic poly(A)-binding proteins, PABPC1 and PABPC2, in mouse spermatogenic cells.	PABPC1 PABPC3	1.82e-05	2	149	2	19020299
Pubmed	Angiotensin II induces MMP 2 activity via FAK/JNK pathway in human endothelial cells.	AGT MMP2	1.82e-05	2	149	2	19338750
Pubmed	Fluorescence resonance energy transfer (FRET) indicates that association with the type I ryanodine receptor (RyR1) causes reorientation of multiple cytoplasmic domains of the dihydropyridine receptor (DHPR) α(1S) subunit.	CACNA1S RYR1	1.82e-05	2	149	2	23071115
Pubmed	TCN1 Deficiency Inhibits the Malignancy of Colorectal Cancer Cells by Regulating the ITGB4 Pathway.	TCN1 ITGB4	1.82e-05	2	149	2	35686504
Pubmed	Functional compensation for the loss of testis-specific poly(A)-binding protein, PABPC2, during mouse spermatogenesis.	PABPC1 PABPC3	1.82e-05	2	149	2	26971890
Pubmed	Comparison of pathogenicity prediction tools on missense variants in RYR1 and CACNA1S associated with malignant hyperthermia.	CACNA1S RYR1	1.82e-05	2	149	2	27147545
Pubmed	Levels of free PABP are limited by newly polyadenylated mRNA in early Spisula embryogenesis.	PABPC1 PABPC3	1.82e-05	2	149	2	10954604
Pubmed	Multiminicore Disease – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY	SELENON RYR1	1.82e-05	2	149	2	20301467
Pubmed	The alpha(1S) III-IV loop influences 1,4-dihydropyridine receptor gating but is not directly involved in excitation-contraction coupling interactions with the type 1 ryanodine receptor.	CACNA1S RYR1	1.82e-05	2	149	2	18556650
Pubmed	Distinct Components of Retrograde Ca(V)1.1-RyR1 Coupling Revealed by a Lethal Mutation in RyR1.	CACNA1S RYR1	1.82e-05	2	149	2	26910427
Pubmed	Selenoprotein N is required for ryanodine receptor calcium release channel activity in human and zebrafish muscle.	SELENON RYR1	1.82e-05	2	149	2	18713863
Pubmed	MEK, ERK, and p90RSK are present on mitotic tubulin in Swiss 3T3 cells: a role for the MAP kinase pathway in regulating mitotic exit.	RPS6KA2 RPS6KA3	1.82e-05	2	149	2	11495723
Pubmed	The mouse gene encoding the testis-specific isoform of Poly(A) binding protein (Pabp2) is an expressed retroposon: intimations that gene expression in spermatogenic cells facilitates the creation of new genes.	PABPC1 PABPC3	1.82e-05	2	149	2	9732454
Pubmed	Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces angiogenesis resulting in impaired growth of regenerated muscle fibers.	MMP2 DMD	1.82e-05	2	149	2	21320869
Pubmed	Morphology and molecular composition of sarcoplasmic reticulum surface junctions in the absence of DHPR and RyR in mouse skeletal muscle.	CACNA1S RYR1	1.82e-05	2	149	2	12023238
Pubmed	Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment.	APOB AGT	1.82e-05	2	149	2	15614026
Pubmed	Dihydropyridine receptor gene expression in skeletal muscle from mdx and control mice.	CACNA1S DMD	1.82e-05	2	149	2	9540851
Pubmed	Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness.	CACNA1S RYR1	1.82e-05	2	149	2	25658027
Pubmed	Quantitative reduction of RyR1 protein caused by a single-allele frameshift mutation in RYR1 ex36 impairs the strength of adult skeletal muscle fibres.	CACNA1S RYR1	1.82e-05	2	149	2	30689883
Pubmed	Elevated MMP2 abundance and activity in mdx mice are alleviated by prenatal taurine supplementation.	MMP2 DMD	1.82e-05	2	149	2	32208990
Pubmed	Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.	RRM2 CDK2	1.82e-05	2	149	2	31649026
Pubmed	RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.	CACNA1S RYR1	1.82e-05	2	149	2	30325262
Pubmed	Plasma membrane calcium-ATPase 2 and 4 in human breast cancer cell lines.	ATP2B2 ATP2B4	1.82e-05	2	149	2	16216224
Pubmed	Overlapping Activities of Two Neuronal Splicing Factors Switch the GABA Effect from Excitatory to Inhibitory by Regulating REST.	PARP6 NRXN3 CADPS ASPH RIMS1 ATP2B2	1.97e-05	128	149	6	30995482
Pubmed	Maternal Transient Receptor Potential Vanilloid 6 (Trpv6) Is Involved In Offspring Bone Development.	TRPC5 RYR1 ATP2B2 ATP2B4	2.13e-05	38	149	4	30786075
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	ATRX RPS6KA2 HECTD4 SRP54 CHD1L SELENON GRHL2 ARRB1 PIK3C3 PTPRR ANKAR ASPH LRP1 KDM2A IFT122 RIMS1 DNAJC3 MAN1B1 KDM4B	2.17e-05	1489	149	19	28611215
Pubmed	Optimized fragmentation schemes and data analysis strategies for proteome-wide cross-link identification.	HK2 ATRX CHD1L DBI PRPF8 PABPC1 DDX46 AHNAK TNKS1BP1 DMD ATP2B2	2.22e-05	538	149	11	28524877
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	DOC2A MON2 RPS6KA2 HECTD4 INO80 KLF4 ITGB4 RYR1 SIRT2 AHNAK PDCD11 TNKS1BP1 CEP131 ZC3H7B RASAL1 BAHCC1	2.28e-05	1105	149	16	35748872
Pubmed	Identification of proximal SUMO-dependent interactors using SUMO-ID.	RANBP2 WBP11 ERCC3 SRP54 RRM2 EMSY AHNAK SENP6 TNKS1BP1 MGA	2.34e-05	444	149	10	34795231
Pubmed	The contribution of rare and common variants in 30 genes to risk nicotine dependence.	ANKK1 NRXN3 NRXN2	2.71e-05	14	149	3	25450229
Pubmed	Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB.	RPS6KA5 RPS6KA2 RPS6KA3	2.71e-05	14	149	3	9687510
Pubmed	Host cell interactome of HIV-1 Rev includes RNA helicases involved in multiple facets of virus production.	ERCC3 HK2 SRP54 PRPF8 PABPC1 PDCD11 PSPC1	3.18e-05	206	149	7	22174317
Pubmed	Intact lipid rafts regulate HIV-1 Tat protein-induced activation of the Rho signaling and upregulation of P-glycoprotein in brain endothelial cells.	MYL2 ABCB4 MYL10	4.14e-05	16	149	3	19794400
Pubmed	Dynamic regulation of sarcoplasmic reticulum Ca(2+) stores by stromal interaction molecule 1 and sarcolipin during muscle differentiation.	CACNA1S TRPC5 RYR1	5.01e-05	17	149	3	22411552
Pubmed	Spinal neural tube closure depends on regulation of surface ectoderm identity and biomechanics by Grhl2.	MYL2 GRHL2 ZEB2	5.01e-05	17	149	3	31171776
Pubmed	Comprehensive Interactome Mapping of the DNA Repair Scaffold SLX4 Using Proximity Labeling and Affinity Purification.	RANBP2 ATRX EMSY ZNF518A SENP6 PDCD11 MGA	5.11e-05	222	149	7	37071664
Pubmed	Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors.	HKDC1 SEC11C PRPF8 SELENON PABPC1 NOMO1 NOMO2 AIFM1 NT5DC2 PABPC3 AHNAK ASPH LRP1 MMP2 PSPC1 DNAJC3 NOMO3 MAN1B1	5.23e-05	1451	149	18	30550785
Pubmed	N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective.	STRN3 RANBP2 ATRX SRP54 PRPF8 PABPC1 EMSY PDLIM5 SIRT2 DDX46 AHNAK SENP6 TNKS1BP1 CDK2	5.24e-05	934	149	14	33916271
Pubmed	Conditional Knockout of Neurexins Alters the Contribution of Calcium Channel Subtypes to Presynaptic Ca2+ Influx.	NRXN3 NRXN2	5.45e-05	3	149	2	38891114
Pubmed	Embryonic Poly(A)-Binding Protein Is Required During Early Stages of Mouse Oocyte Development for Chromatin Organization, Transcriptional Silencing, and Meiotic Competence.	PABPC1 PABPC3	5.45e-05	3	149	2	26134869
Pubmed	Iron regulatory protein-1 protects against mitoferrin-1-deficient porphyria.	ACO1 ALAS2	5.45e-05	3	149	2	24509859
Pubmed	Human testis expresses a specific poly(A)-binding protein.	PABPC1 PABPC3	5.45e-05	3	149	2	11328870
Pubmed	Superovulation alters embryonic poly(A)-binding protein (Epab) and poly(A)-binding protein, cytoplasmic 1 (Pabpc1) gene expression in mouse oocytes and early embryos.	PABPC1 PABPC3	5.45e-05	3	149	2	25034140
Pubmed	Interplay between KLF4 and ZEB2/SIP1 in the regulation of E-cadherin expression.	KLF4 ZEB2	5.45e-05	3	149	2	23376074
Pubmed	Exome-wide association study identifies genetic polymorphisms of C12orf51, MYL2, and ALDH2 associated with blood lead levels in the general Korean population.	MYL2 HECTD4	5.45e-05	3	149	2	28212632
Pubmed	Increased matrix-metalloproteinase-2 and matrix-metalloproteinase-9 expression in the brain of dystrophic mdx mouse.	MMP2 DMD	5.45e-05	3	149	2	16650610
Pubmed	MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4.	KLF4 MMP2	5.45e-05	3	149	2	24281002
Pubmed	Angiotensin II Downregulates MicroRNA-145 to Regulate Kruppel-like Factor 4 and Myocardin Expression in Human Coronary Arterial Smooth Muscle Cells under High Glucose Conditions.	KLF4 MYOCD	5.45e-05	3	149	2	26181633
Pubmed	CircEHMT1 inhibits metastatic potential of breast cancer cells by modulating miR-1233-3p/KLF4/MMP2 axis.	KLF4 MMP2	5.45e-05	3	149	2	32209259
Pubmed	Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.	S100P CDK2	5.45e-05	3	149	2	19885547
Pubmed	Interaction between the dihydropyridine receptor Ca2+ channel beta-subunit and ryanodine receptor type 1 strengthens excitation-contraction coupling.	CACNA1S RYR1	5.45e-05	3	149	2	16357209
Pubmed	alpha-Neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction.	NRXN3 NRXN2	5.45e-05	3	149	2	16406382
Pubmed	SIRT1 Functions as a Negative Regulator of Eukaryotic Poly(A)RNA Transport.	PABPC1 PABPC3	5.45e-05	3	149	2	28756945
Pubmed	The poly(A)-binding protein genes, EPAB, PABPC1, and PABPC3 are differentially expressed in infertile men with non-obstructive azoospermia.	PABPC1 PABPC3	5.45e-05	3	149	2	26843391
Pubmed	Triad proteins and intracellular Ca2+ transients during development of human skeletal muscle cells in aneural and innervated cultures.	CACNA1S RYR1	5.45e-05	3	149	2	11206130
GeneFamily	Mitogen-activated protein kinase-activated protein kinases	RPS6KA5 RPS6KA2 RPS6KA3	2.18e-05	11	94	3	1156
GeneFamily	Phosphatidylinositol 3-kinase subunits	PIK3C2G PIK3C3	7.34e-04	8	94	2	831
GeneFamily	ATPases Ca2+ transporting	ATP2B2 ATP2B4	9.40e-04	9	94	2	1209
GeneFamily	Myosin light chains\|EF-hand domain containing	MYL2 MYL10	2.34e-03	14	94	2	657
GeneFamily	X-linked mental retardation\|Angiotensin receptors	ATRX RPS6KA3 DMD	2.64e-03	53	94	3	103
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	ADNP2 ZEB2	2.69e-03	15	94	2	529
GeneFamily	DNA helicases	ERCC3 INO80	3.46e-03	17	94	2	1167
GeneFamily	Zinc fingers\|Zinc fingers PARP-type\|Poly(ADP-ribose) polymerases	PARP6 PARP9	3.46e-03	17	94	2	684
GeneFamily	RNA binding motif containing	PTBP3 CELF5 PABPC1 PABPC3 PSPC1	5.09e-03	213	94	5	725
GeneFamily	Protein tyrosine phosphatases, receptor type	PTPRD PTPRR	5.27e-03	21	94	2	813
GeneFamily	EF-hand domain containing	MYL2 EFHB SELENON S100P MYL10	5.72e-03	219	94	5	863
GeneFamily	PHD finger proteins\|Lysine demethylases	KDM2A KDM4B	6.85e-03	24	94	2	485
Coexpression	GAL_LEUKEMIC_STEM_CELL_UP	ALS2CL ITGB4 PDLIM5 PIK3C3 AGT SENP6 ZC3H7B	8.98e-06	130	147	7	M17428
Coexpression	FULLER_PBMC_F_TULARENSIS_VACCINE_LVS_AGE_22_54YO_18HR_TO_336HR_SUSTAINED_UP	SPN ARRB1 LRP1	1.42e-05	9	147	3	M41059
Coexpression	GSE360_T_GONDII_VS_B_MALAYI_LOW_DOSE_DC_UP	ATRX RGS1 ZNF518A RFTN1 TESK2 KDM2A IFI44L KDM4B	1.61e-05	197	147	8	M5217
Coexpression	BUSSLINGER_DUODENAL_MATURE_ENTEROCYTES	CIDEB ABHD3 HKDC1 APOB KLF4 ITGB4 ATG4B AHNAK LRP1	1.64e-05	259	147	9	M40029
Coexpression	IGARASHI_ATF4_TARGETS_DN	RPS6KA3 KLF4 S100P ARRB1 ASPH AP5M1	1.93e-05	98	147	6	M4779
Coexpression	NAKAYA_PBMC_FLUARIX_FLUVIRIN_AGE_18_50YO_CORRELATED_WITH_HAI_28DY_RESPONSE_AT_7DY_POSITIVE	CIDEB SEC11C RRM2 EMSY NOMO1 NOMO2 NOMO3	3.73e-05	162	147	7	M41204
Coexpression	GABRIELY_MIR21_TARGETS	PTBP3 ATRX RPS6KA3 DDX46 VPS13A PARP9 DMD MGA ATP2B4	3.88e-05	289	147	9	M2196
ToppCell	droplet-Marrow-BM_(NON-STC)-30m-Myeloid-basophil\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DBI KLF4 DDX46 NT5DC2 AHNAK FAM210B LRP1 ALAS2 ATP2B4	8.86e-09	178	148	9	1a578d16008a450c42e73a996247ffecdc2c43f0
ToppCell	COVID_vent-Lymphocytic-Plasma_cell-IgA_Plasmablast\|COVID_vent / Disease condition, Lineage, Cell class and subclass	SRP54 SEC11C RRM2 NOMO1 NOMO2 NT5DC2 BUB1 DNAJC3 NOMO3	2.14e-08	197	148	9	99fe44ef42c65d24fe64947fd5bf6d91b9a4b2c3
ToppCell	droplet-Heart-nan-3m\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RANBP2 ATRX RPS6KA3 SRP54 ZEB2 AHNAK MYOCD DMD	1.38e-07	176	148	8	749b47eac5436fa34e0d243ffbc6f1897f4e431e
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Neuronal-neuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TRPC5 NRIP3 ARRB1 NRXN3 CADPS SLC6A5 ATP2B2 UNC80	2.29e-07	188	148	8	1efbc99bcd6542e5d9fa91edb7c4295167914786
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CELF5 NRXN3 PTPRR CADPS RIMS1 ATP2B2 UNC80 CDH18	3.14e-07	196	148	8	676c56b44ac29f7baecb62f49bb8597cc74c0a88
ToppCell	Control-Control-Lymphocyte-T/NK-NK_activated\|Control / Disease, condition lineage and cell class	DOC2A SPN NRXN2 AHNAK TNKS1BP1 PARP9 IFI44L ATP2B4	3.40e-07	198	148	8	76d5fe4e5bbe6c73a6ca409b80b5c3924e07cab7
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	CELF5 NRXN3 PTPRR CADPS RIMS1 ATP2B2 UNC80 CDH18	3.40e-07	198	148	8	0ff30edfd3c133a42e8cb96e1631a1143215f808
ToppCell	Neuronal\|World / cells hierarchy compared to all cells using T-Statistic	CELF5 NRXN3 PTPRR CADPS RIMS1 ATP2B2 UNC80 CDH18	3.67e-07	200	148	8	48d801219bc771d6c7e151dc88ca4c179988de85
ToppCell	COVID-19-kidney-Technical/muscle_(Imm)\|kidney / Disease (COVID-19 only), tissue and cell type	IKZF1 RYR1 NRXN3 PTPRR CADPS DMD CDH18	1.25e-06	163	148	7	19c28ce16a588a7f4a035c32726f6ccd67702b5b
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Immune-Myeloid-Granulocytic-Mast_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	INTS6L HK2 RPS6KA5 LDHAL6B IKZF1 RGS1 CADPS	1.31e-06	164	148	7	2c48c6e4eeee845f0563982d0bfa2a176ca5ef61
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro-Astrocyte-Astro_L1_FGFR3_FOS\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PIRT DBI ITGB4 SERPINI2 AHNAK AGT IFI44L	2.17e-06	177	148	7	191c14e0ef162536028b841f3759aaddef59b49d
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Immune-Myeloid-Granulocytic\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	INTS6L HK2 LDHAL6B IKZF1 RGS1 S100P CADPS	2.25e-06	178	148	7	af9bcee71fb44a6342d4b92bba5b8ddfeeaa24b2
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SFTA2 AP1M2 SEC11C GRHL2 S100P NRXN3 CDH18	2.43e-06	180	148	7	b798a3fa2dd15b68aa4267f665559527043dcc07
ToppCell	Mid-temporal_gyrus_(MTG)-Non-neuronal-Macroglial-Astro-Astrocyte-Astro_L1_FGFR3_MT1G\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	HKDC1 DBI ITGB4 PDLIM5 SERPINI2 AHNAK AGT	3.01e-06	186	148	7	41e03be964044dae690d566bd078dab3d8045eba
ToppCell	Entopeduncular-Neuronal\|Entopeduncular / BrainAtlas - Mouse McCarroll V32	CELF5 TRPC5 NRIP3 NRXN3 CADPS ATP2B2 UNC80	3.72e-06	192	148	7	4c35e5c28a40b439044797ba1f06cb7c36b2a8de
ToppCell	severe-Plasmablast\|severe / disease stage, cell group and cell class	SRP54 SEC11C RRM2 NOMO1 NT5DC2 BUB1 DNAJC3	4.12e-06	195	148	7	e11616ad568e50e4c720b50b0c071f484c31d16b
ToppCell	Somatosensory_Cortex_(S1)-Neuronal\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NRXN3 PTPRR CADPS RIMS1 ATP2B2 UNC80 CDH18	4.55e-06	198	148	7	c01091ef18e096d792ea2a7a715764a5b215355f
ToppCell	primary_auditory_cortex_(A1C)-Neuronal\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NRXN3 PTPRR CADPS RIMS1 ATP2B2 UNC80 CDH18	4.55e-06	198	148	7	6d18b45eda4014759e6dd282d78ffd28df8a6044
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	NRXN3 PTPRR CADPS RIMS1 ATP2B2 UNC80 CDH18	4.55e-06	198	148	7	4ca5ff320905ab4ff60ed90a5522227c782142a6
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW23-Neuronal-GABAergic_neurons\|GW23 / Sample Type, Dataset, Time_group, and Cell type.	RPS6KA2 NRIP3 ZEB2 NRXN3 NRXN2 PTPRR CADPS	4.86e-06	200	148	7	c6bbd33bca86ac7a76a7ba704b3e141237d04549
ToppCell	Control-Plasmablast\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	SPN SEC11C NOMO1 NOMO2 NT5DC2 AHNAK	9.13e-06	145	148	6	fe68582f5a15b9714cb84fa32ac880e13cb69895
ToppCell	RV-16._Neuronal\|World / Chamber and Cluster_Paper	MYL2 ITGB4 FAM135B NRXN3 AHNAK AGT	1.07e-05	149	148	6	3a2f8c4173dcf9e3f8d3b8ffddbc597098adf7a9
ToppCell	facs-Liver-Hepatocytes\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TCN1 ACO1 ABHD3 ABCB4 PTPRD AGT	1.39e-05	156	148	6	e2cda3ad4e5f44a80133864c5a38b766afb952ce
ToppCell	Fetal_29-31_weeks-Epithelial-lung_neuroendocrine_cell_(PNEC)-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	SEC11C CADPS TRPV3 RIMS1 UNC80 CDH18	1.54e-05	159	148	6	7747cef94c55144fddcd024a7495318357f1351b
ToppCell	COVID-19-kidney-Technical/muscle_(Mes)\|kidney / Disease (COVID-19 only), tissue and cell type	RYR1 NRXN3 CADPS RIMS1 DMD CDH18	1.54e-05	159	148	6	5335cbcdeaf2bbd0268bbfe0e45c8c0d288e640d
ToppCell	droplet-Heart-HEART_(LV+RV_ONLY)-30m-Hematologic-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SPN PABPC1 RYR1 FAM210B ALAS2	1.73e-05	96	148	5	7a1a27d996c2bbcd922da524969f568f0575dfad
ToppCell	PND10-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-ILC-ILC_prolif\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	RPS6KA5 SPN SEC11C RRM2 RGS1 ANKAR	2.18e-05	169	148	6	20fbf78382fb0ba9a63ab1aa0abc615476994ac5
ToppCell	TCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma-4\|TCGA-Liver / Sample_Type by Project: Shred V9	COX19 ABHD3 SLC6A11 ATG4B HECTD2 NT5DC2	2.18e-05	169	148	6	0a3ba6b5d6cff9d3d7f56046063cfc3a37ae1156
ToppCell	PND14-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-ILC-ILC_G2M\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	RPS6KA5 SPN RRM2 PABPC1 RGS1 BUB1	2.25e-05	170	148	6	b04e2f84024baaae9b4ff19bdac8c69afdb92a76
ToppCell	primary_auditory_cortex_(A1C)-Non-neuronal-Macroglial-Astro-Astrocyte-Astro_L1_FGFR3_FOS\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	HK2 PIRT ITGB4 SERPINI2 AHNAK AGT	2.57e-05	174	148	6	53c2c132566a7682f3268c7f9138700f09c3b94d
ToppCell	COVID-19-lung-MAST\|COVID-19 / Disease (COVID-19 only), tissue and cell type	INTS6L RPS6KA5 IKZF1 RGS1 ZEB2 CADPS	2.74e-05	176	148	6	473c45a381ca109207d66ed1635668b391ea0e1f
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_A_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATRX KLF4 PTPRD PIK3C2G AGT DMD	2.83e-05	177	148	6	426a9845df7fd13b02e744532c336c60bc4d4a22
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_A_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	KLF4 NRXN3 PTPRD PIK3C2G AGT DMD	2.83e-05	177	148	6	1dc69c661e70e7e22bd9d7cf953eb638da9fd43c
ToppCell	facs-Lung-18m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l27\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ENPP6 ITGB4 ABCB4 PTPRR ATP2B2 ATP2B4	2.83e-05	177	148	6	d68132e145bd413404fdbe215b5dbe520e756e50
ToppCell	droplet-Spleen-nan-24m-Hematologic-nan\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRM2 ABCB4 NT5DC2 FAM210B ALAS2 ATP2B4	3.01e-05	179	148	6	f3f9c7e575bc4d9d3bce649b90254182e8f6aaec
ToppCell	droplet-Lung-3m-Epithelial-alveolar_epithelial-type_I_pneumocyte-type_1_alveolar_epithelial_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SFTA2 CIDEB CACNA1S TCN1 GRHL2 PIK3C2G	3.01e-05	179	148	6	ca70a5518c5a5392e088c103e0cb44aa084f5332
ToppCell	droplet-Lung-3m-Epithelial-alveolar_epithelial-type_I_pneumocyte\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	SFTA2 CIDEB CACNA1S TCN1 GRHL2 PIK3C2G	3.01e-05	179	148	6	c451b074b04eb5d6c575c6abaedda579c6744bbf
ToppCell	droplet-Spleen-nan-24m-Hematologic\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRM2 ABCB4 NT5DC2 FAM210B ALAS2 ATP2B4	3.01e-05	179	148	6	01e0b49e7f03ac9c3e6c34708ead300d27236b8b
ToppCell	3'-Distal_airway-Immune_Lymphocytic-Lymphocytic_T/NK-CD4-positive,_alpha-beta_T_cell-CD4_T_cells-CD4_T_cells_L.1.1.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	INTS6L SCLY RFTN1 HECTD2 VPS13A SENP6	3.01e-05	179	148	6	6bbb32d7e582a96cb3cfc3eb911b05d518e7d5e9
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_2-AT2_Progenitor\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SFTA2 SEC11C DBI GRHL2 S100P NRXN3	3.01e-05	179	148	6	7db6b97a1c4c7a163d5da4351ba36ac1785d9d7b
ToppCell	facs-Brain_Non-Myeloid-Hippocampus_-18m-Macroglial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PIRT SEC11C DBI SIRT2 NRXN2 MMP2	3.20e-05	181	148	6	1037051eb82313c13346617b33f3c4c648181c4d
ToppCell	droplet-Marrow-nan-3m-Hematologic-nan\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATRX SRP54 RGS1 JAK1 VPS13A SENP6	3.30e-05	182	148	6	e78ba2c5cae480c16a596ce7c3bf2d480becacf4
ToppCell	droplet-Marrow-nan-3m-Hematologic\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATRX SRP54 RGS1 JAK1 VPS13A SENP6	3.30e-05	182	148	6	1710eab3037a87609d21838be2d2d29c3bc36651
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APOB PTPRD PIK3C2G MYOCD DMD UNC80	3.51e-05	184	148	6	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Epithelial-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ANKK1 FBXW10 EFHB CFAP54 TESK2 AGT	3.51e-05	184	148	6	6b0c110d8930df99043c3b99cf4d873985126960
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Epithelial\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ANKK1 FBXW10 EFHB CFAP54 TESK2 AGT	3.51e-05	184	148	6	35928fc5f7bbf8c7b09181a2bd27e22dff42ec16
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APOB PTPRD PIK3C2G MYOCD DMD UNC80	3.51e-05	184	148	6	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	APOB PTPRD PIK3C2G MYOCD DMD UNC80	3.51e-05	184	148	6	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Glutamatergic_Excit\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	PTPRD PTPRR VPS13A ATP2B4 RASAL1 CDH18	3.73e-05	186	148	6	84ba666237c18189d7e7556bd92dd953af733c00
ToppCell	droplet-Lung-21m-Endothelial-arterial_endothelial-pulmonary_artery_endothelial_cell-pulmonary_artery_endothelial_cell_l27\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ENPP6 ITGB4 PTPRR TNKS1BP1 ATP2B2 ATP2B4	3.73e-05	186	148	6	c116cc9f41971622264434ebe29d18e719b0ae19
ToppCell	droplet-Spleen-SPLEEN-30m-Hematologic-nan\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRM2 ABCB4 NT5DC2 BUB1 ALAS2 ATP2B4	3.73e-05	186	148	6	7cdcf507a9a1349ed2cf62b79116367c3fc732dd
ToppCell	droplet-Spleen-SPLEEN-30m-Hematologic\|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RRM2 ABCB4 NT5DC2 BUB1 ALAS2 ATP2B4	3.73e-05	186	148	6	ac6e32cf07f0f013101ca7aedae0c562857f182b
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Non-neuronal-Macroglial-Astro-Astrocyte-Astro_L1_FGFR3_MT1G\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	HKDC1 ITGB4 SERPINI2 AHNAK AGT IFI44L	3.84e-05	187	148	6	2b1b2c3792d6c9ab69675ce88842bb589414b530
ToppCell	LPS-IL1RA-Epithelial_alveolar\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SFTA2 AP1M2 SEC11C GRHL2 S100P NRXN3	3.96e-05	188	148	6	6164d467b612767ceba15de34176bcc8e8c36ab8
ToppCell	Endothelial-Endothelial-E\|Endothelial / shred on cell class and cell subclass (v4)	ENPP6 ITGB4 NRXN3 PTPRR MMP2 ATP2B4	3.96e-05	188	148	6	2777eb7689b271c199021fe7d9db88ccebff14de
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Neuronal-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NRIP3 NRXN3 NRXN2 RIMS1 UNC80 CDH18	4.08e-05	189	148	6	f57200c93d39c9bce1adba0a6a1c178c028dd86b
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PDLIM5 RFTN1 CADPS MYOCD DMD ATP2B4	4.20e-05	190	148	6	2e88e366d377d74deb53a4ea870973ce5c6532e8
ToppCell	3'-Broncho-tracheal-Epithelial-Neuro-endocrine/ionocytic-lung_neuroendocrine_cell-Neuroendocrine\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	SEC11C CADPS AGT SLC6A5 UNC80 CDH18	4.20e-05	190	148	6	40d8b3403f4e38436b961cd3a2e69826cbae3042
ToppCell	3'-Broncho-tracheal-Epithelial-Neuro-endocrine/ionocytic-lung_neuroendocrine_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	SEC11C CADPS AGT SLC6A5 UNC80 CDH18	4.20e-05	190	148	6	a9a705455019e28d655636de73b07540798f82e6
ToppCell	renal_medulla_nuclei-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PDLIM5 RFTN1 CADPS MYOCD DMD ATP2B4	4.20e-05	190	148	6	0028f886c789ba238c031eae5d96acaed4af8c25
ToppCell	droplet-Heart-nan-3m-Mesenchymal\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SRP54 ZEB2 ASPH LRP1 MYOCD MMP2	4.20e-05	190	148	6	96a92212ea3fb35fa3d0da495e504edc61c71c23
ToppCell	3'-Broncho-tracheal-Epithelial-Neuro-endocrine/ionocytic-lung_neuroendocrine_cell-Neuroendocrine-Neuroendocrine_L.0.7.2.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	SEC11C CADPS AGT SLC6A5 UNC80 CDH18	4.20e-05	190	148	6	f6cbf6d292f488ada5f7581e1dceba6198b933d1
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DCHS2 ZEB2 PDLIM5 RFTN1 LRP1 DMD	4.32e-05	191	148	6	a6c57627077fa980b7ec1d3894b5f31bfb11b738
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-CD4/CD8-Prolif_T-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	PTBP3 SPN RPS6KA3 IKZF1 RRM2 BUB1	4.32e-05	191	148	6	912e2d10d3423aa7f708fcf2b11da1845f12d7d3
ToppCell	Control-Plasmablast\|Control / disease group and sub_cluster of B and Plasma cells(res = 0.5)	SPN SEC11C NOMO1 NOMO2 NT5DC2 DNAJC3	4.32e-05	191	148	6	3df5bbdb29bbcbcb8476fdf126b6d4c1ac67d64b
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Lymphoid-CD4/CD8-Prolif_T\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	PTBP3 SPN RPS6KA3 IKZF1 RRM2 BUB1	4.32e-05	191	148	6	77a2746b6d9c53b08d4405411c16fcc5a6c734ce
ToppCell	PBMC_fresh-frozen-Mild-Moderate_progression_d12-25\|PBMC_fresh-frozen / Compartment, severity and other cell annotations on 10x 3' data (130k)	RANBP2 WBP11 RGS1 KDM2A ALAS2 IFI44L	4.32e-05	191	148	6	1ecd9849d14d5ebf3daf610e83fb50820cafd3ed
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Collagen+matrisome-high_fibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	DCHS2 ZEB2 PDLIM5 RFTN1 LRP1 DMD	4.32e-05	191	148	6	8f6d592edc32fdb901af30501d4360512334e8c2
ToppCell	COVID-19_Severe-Lymphoid_P\|COVID-19_Severe / Disease group, lineage and cell class	SRP54 SEC11C RRM2 NOMO1 NT5DC2 BUB1	4.45e-05	192	148	6	3d0240491296757b3125f6e861bbaca06bbc5068
ToppCell	COVID-19_Severe-Lymphoid_P-Plasmablast\|COVID-19_Severe / Disease group, lineage and cell class	SRP54 SEC11C RRM2 NOMO1 NT5DC2 BUB1	4.45e-05	192	148	6	90af8dad4e6f80b5ecd62027deeb2e4cea6b24bb
ToppCell	PBMC-Severe-Lymphocyte-B-Plasmablast\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	SRP54 SEC11C RRM2 NOMO1 NT5DC2 BUB1	4.58e-05	193	148	6	227d82059a9f99937e0188ff57f2d0e485ebfe69
ToppCell	facs-Brain_Non-Myeloid-Cortex-24m-Neuronal-neuron\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CELF5 NRXN3 NRXN2 ATP2B2 ATP2B4 UNC80	4.58e-05	193	148	6	8689a70a33a7c3823dc647d41ac0160e7c3ae396
ToppCell	PBMC-Severe-Lymphocyte-B-Plasmablast\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SRP54 SEC11C RRM2 NOMO1 NT5DC2 BUB1	4.58e-05	193	148	6	ce3873ece35fd2155ea235cb3c8bcd235cc0ebde
ToppCell	PBMC-Severe-Lymphocyte-B-Plasmablast-Plasmablast\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SRP54 SEC11C RRM2 NOMO1 NT5DC2 BUB1	4.58e-05	193	148	6	8f57b0473a2c2c07f83e5fe70f16862b1bb3b514
ToppCell	facs-Brain_Non-Myeloid-Cerebellum-24m-Neuronal\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NRIP3 NRXN3 NRXN2 RIMS1 UNC80 CDH18	4.58e-05	193	148	6	5fb7808dd971c1cc64c2bd4f8f1de646fb2d77f4
ToppCell	facs-Brain_Non-Myeloid-Cortex-24m-Neuronal\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CELF5 NRXN3 NRXN2 ATP2B2 ATP2B4 UNC80	4.58e-05	193	148	6	be28070c049e7cb68bcd54f582226eb2f5e4bc1c
ToppCell	PBMC-Severe-Lymphocyte-B-Plasmablast-Plasmablast-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	SRP54 SEC11C RRM2 NOMO1 NT5DC2 BUB1	4.58e-05	193	148	6	38bb14df7f05c29565a1c7f175fafe636e543bf8
ToppCell	PBMC-Severe-Lymphocyte-B-Plasmablast-Plasmablast\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	SRP54 SEC11C RRM2 NOMO1 NT5DC2 BUB1	4.58e-05	193	148	6	3ba6d44248690b80f4caf791d463e60f1ab816c4
ToppCell	facs-Brain_Non-Myeloid-Cortex-24m-Neuronal-nan\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CELF5 NRXN3 NRXN2 ATP2B2 ATP2B4 UNC80	4.58e-05	193	148	6	0c652ebe22ce5d2927599dd97ef1920547858395
ToppCell	droplet-Marrow-BM_(NON-STC)-30m-Myeloid-promonocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	DBI KLF4 ZEB2 AHNAK LRP1 MFSD1	4.58e-05	193	148	6	5a201ee6f132357c9aacfbad3ae56ed9854c25fd
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-DC-cDC2-F\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	RPS6KA3 KLF4 PABPC1 RGS1 PRX IFI44L	4.85e-05	195	148	6	cb27f6ca8b02438c353c9dff2f76d2656bb5b29a
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATRX RPS6KA2 CADPS VPS13A MGA UNC80	4.85e-05	195	148	6	7796ea9247f4c63762f0de8490fed08b9717fa23
ToppCell	Secretory\|World / shred by cell class for bronchial biopsy	HK2 TCN1 RPS6KA3 SEC11C S100P RIMS1	4.85e-05	195	148	6	52f8281fe0df67cec3faa780a23ed6343ed5a6ba
ToppCell	control-Lymphoid-Treg\|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	SPN SLC35G2 RGS1 ANKAR IFI44L ATP2B4	4.85e-05	195	148	6	66959ae839eb60a573da06bdd227090ebb5bb9ed
ToppCell	COVID-19-T_cells-Cycling_NK/T_cells\|COVID-19 / group, cell type (main and fine annotations)	KNTC1 SPN IKZF1 RRM2 BUB1 ALAS2	4.85e-05	195	148	6	764ed100c28d9bc93ee5ecabc5291c8f184d78da
ToppCell	metastatic_Brain-Myeloid_cells-Microglia/Mac\|metastatic_Brain / Location, Cell class and cell subclass	DBI KLF4 RGS1 ZEB2 LRP1 MFSD1	4.85e-05	195	148	6	ae48d493ebda5f87781181a3d1d73d8f84fc5e77
ToppCell	droplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ATRX RPS6KA2 CADPS VPS13A MGA UNC80	4.85e-05	195	148	6	3e519cffa6144a62b06124642a14c9ff39b76554
ToppCell	droplet-Limb_Muscle-MUSCLE-30m-Mesenchymal\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	HK2 ATRX SRP54 PTPRD LRP1 MMP2	4.85e-05	195	148	6	5c86fddd6d0530beecf45ea5ba6b823123847696
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ZEB2 PDLIM5 RFTN1 CADPS MYOCD DMD	4.99e-05	196	148	6	1522958a92e0126326a9f0d9fb1c5b5c50b001ea
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Myofibroblast-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ZEB2 PDLIM5 RFTN1 CADPS MYOCD DMD	4.99e-05	196	148	6	1c8294014713684b50885e638668f2ce75f357f0
ToppCell	Mild/Remission-Plasmablast\|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5)	SPN SRP54 SEC11C NOMO1 NT5DC2 DNAJC3	4.99e-05	196	148	6	dcf0a804a79a05454658498d1f87320c7e079219
ToppCell	10x_3'_v3-blood_(10x_3'_v3)-myeloid-myeloid_monocytic-classical_monocyte\|blood_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	KLF4 PABPC1 ZEB2 AHNAK LRP1 MFSD1	4.99e-05	196	148	6	28e9e191361966df3a9bd48450090577aa72a999
ToppCell	Bronchial-NucSeq-Epithelial-Epi_airway_neuro-secretory-Neuroendocrine\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	RRM2 NRIP3 FAM135B CADPS ASTN1 UNC80	4.99e-05	196	148	6	4bdc304c0c9d8bebe1a6a8a27e44acd1e8113725
ToppCell	11.5-Distal-Epithelial\|Distal / Age, Tissue, Lineage and Cell class	SFTA2 AP1M2 SEC11C GRHL2 PIK3C2G DMD	5.14e-05	197	148	6	ae9505ae7e6c5e8c280f9bfb1ba79ab5bd8895e3
ToppCell	Severe\|World / disease group and sub_cluster of B and Plasma cells(res = 0.5)	SEC11C RRM2 NOMO1 NT5DC2 BUB1 DNAJC3	5.14e-05	197	148	6	df3f58b58f82c42c65b0a09c054b669b34502037
ToppCell	Parenchymal-10x3prime_v2-Epithelial-Epi_airway_ciliated-Deuterosomal\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	DOC2A FBXW10 RRM2 ZNF610 SERPINI2 BUB1	5.14e-05	197	148	6	861e8df9bd74dc5e17bafdc1fb3fef546753c73a
ToppCell	mLN-(2)_B_cell-(20)_B_cell_IgA_Plasma\|mLN / shred on region, Cell_type, and subtype	KNTC1 TCN1 SEC11C NT5DC2 DNAJC3 CDH18	5.14e-05	197	148	6	a39b384ee9824a08c3b544a9c3c7f0f95f08d6a7
ToppCell	TCGA-Pancreas-Primary_Tumor-Pancreatic_Adenocarcinoma-Ductal_Adenocarcinoma\|TCGA-Pancreas / Sample_Type by Project: Shred V9	SFTA2 TCN1 HKDC1 GRHL2 ITGB4 S100P	5.14e-05	197	148	6	d8355f07a53e771052f9ab6b38814365dfe8d9ae
ToppCell	mLN-B_cell-B_cell_IgA_Plasma\|mLN / Region, Cell class and subclass	KNTC1 TCN1 SEC11C NT5DC2 DNAJC3 CDH18	5.14e-05	197	148	6	20822fce311326765b71337ce501ba44ea14f58f
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW19-Neuronal-Interneuron\|GW19 / Sample Type, Dataset, Time_group, and Cell type.	IKZF1 RYR1 NRXN3 PTPRR UNC80	5.26e-05	121	148	5	b2d571f571133c281d72584fe925cebbd2317829
Drug	fluo-3	CACNA1S RYR1 PTPRD AGT SLC6A5 RIMS1 ATP2B2 ATP2B4	1.23e-06	122	146	8	CID000104978
Drug	Gramine [87-52-5]; Up 200; 23uM; MCF7; HT_HG-U133A	RPS6KA2 TRPC5 ALS2CL BUB1 ASPH MMP2 ZC3H7B MYL10 BAHCC1	4.28e-06	192	146	9	2799_UP
Drug	STOCK1N-35215; Down 200; 10uM; PC3; HT_HG-U133A	SPN TRPC5 ITGB4 RYR1 BUB1 ASPH RIMS1 ZC3H7B CDK2	4.65e-06	194	146	9	6380_DN
Drug	Loracarbef [121961-22-6]; Down 200; 10.8uM; HL60; HT_HG-U133A	STRN3 ATRX ALS2CL PDLIM5 ABCB4 ASPH MYL10 EDRF1 KDM4B	5.27e-06	197	146	9	2970_DN
Drug	Bethanechol chloride [590-63-6]; Down 200; 20.4uM; HL60; HT_HG-U133A	MON2 STRN3 ATRX SPN RPS6KA2 KLF4 ABCB4 ASPH KDM4B	5.27e-06	197	146	9	2975_DN
Drug	Oxalamine citrate salt [1949-20-8]; Down 200; 9.2uM; PC3; HT_HG-U133A	CIDEB RPS6KA2 TRPC5 SCLY PDLIM5 PTPRR LRP1 ZC3H7B KDM4B	5.72e-06	199	146	9	6624_DN
Drug	NSC618487	MYL2 RPS6KA5 SPN RPS6KA2 RPS6KA3 APOB JAK1 SIRT2 PIK3C2G PIK3C3 AIFM1 AGT SLC6A5 PARP9 MMP2 MYL10 ATP2B2 ATP2B4 CDK2	8.54e-06	933	146	19	CID000005279
Drug	KB-R7943	CACNA1S MYL2 TRPC5 RYR1 ATP2B2	1.25e-05	47	146	5	CID004534086
Drug	nifedipine	CACNA1S MYL2 ACO1 TRPC5 LDHAL6B DBI RYR1 AGT MMP2 MYL10 ATP2B2 ATP2B4	1.57e-05	415	146	12	CID000004485
Drug	lanthanum	CACNA1S TRPC5 RYR1 AIFM1 RIMS1 ATP2B2 ATP2B4	2.83e-05	136	146	7	CID000023926
Drug	Amethopterin (R,S) [59-05-2]; Down 200; 8.8uM; MCF7; HT_HG-U133A	DOC2A CIDEB PTBP3 SPN FAM210B BUB1 KDM4B BAHCC1	3.09e-05	189	146	8	3214_DN
Drug	Alprenolol hydrochloride [13707-88-5]; Down 200; 14uM; MCF7; HT_HG-U133A	ATRX ALS2CL EMSY FAM210B BUB1 ASPH ZC3H7B RASAL1	3.45e-05	192	146	8	3188_DN
Drug	Selegiline hydrochloride [14611-52-0]; Down 200; 17.8uM; MCF7; HT_HG-U133A	PTBP3 RPS6KA2 ALS2CL ZNF3 ARRB1 ASPH ZC3H7B BAHCC1	3.58e-05	193	146	8	4146_DN
Drug	2-propylpentanoic acid; Down 200; 1000uM; MCF7; HT_HG-U133A	RPS6KA5 RPS6KA2 ITGB4 EMSY MYL10 EDRF1 RASAL1 BAHCC1	4.00e-05	196	146	8	5569_DN
Drug	Benzydamine hydrochloride [132-69-4]; Up 200; 11.6uM; MCF7; HT_HG-U133A	CIDEB PTBP3 ATRX RPS6KA5 RPS6KA2 TAF1C VPS13A ATP2B4	4.14e-05	197	146	8	7169_UP
Drug	Monobenzone [103-16-2]; Up 200; 20uM; MCF7; HT_HG-U133A	CIDEB TAF1C ASPH SENP6 MYL10 ATP2B4 RASAL1 KDM4B	4.14e-05	197	146	8	5312_UP
Drug	Adrenosterone [382-45-6]; Up 200; 13.4uM; PC3; HT_HG-U133A	CIDEB SCLY ITGB4 RYR1 SERPINI2 DMD KDM4B BAHCC1	4.14e-05	197	146	8	5045_UP
Drug	Sulfamonomethoxine [1220-83-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A	PTBP3 STRN3 SPN IKZF1 ITGB4 ZC3H7B EDRF1 RASAL1	4.14e-05	197	146	8	3484_DN
Drug	Mefexamide hydrochloride [3413-64-7]; Down 200; 12.6uM; HL60; HG-U133A	RPS6KA5 SPN RGS1 ZEB2 ZNF3 VPS13A MYL10 DNAJC3	4.30e-05	198	146	8	1438_DN
Drug	Phenelzine sulfate [156-51-4]; Down 200; 17uM; HL60; HT_HG-U133A	PTBP3 SPN ITGB4 RGS1 PDLIM5 VPS13A KDM2A IFT122	4.45e-05	199	146	8	2357_DN
Drug	Methiazole; Up 200; 15uM; MCF7; HT_HG-U133A	RPS6KA2 ABHD3 PDLIM5 PRX AHNAK ASPH KDM4B CDH18	4.45e-05	199	146	8	3878_UP
Drug	Tetracaone hydrochloride [136-47-0]; Up 200; 13.2uM; HL60; HG-U133A	PTBP3 RANBP2 TCN1 SERPINI2 ASPH MYL10 DNAJC3 KDM4B	4.45e-05	199	146	8	1739_UP
Drug	Serotonin hydrochloride [153-98-0]; Up 200; 18.8uM; HL60; HT_HG-U133A	PTBP3 IKZF1 SCLY ARRB1 FAM210B BUB1 ASPH ZC3H7B	4.45e-05	199	146	8	2449_UP
Drug	Piperine [94-62-2]; Up 200; 14uM; PC3; HT_HG-U133A	PTBP3 NRIP3 PDLIM5 NRXN3 PTPRR AHNAK FAM210B ATP2B4	4.45e-05	199	146	8	4247_UP
Drug	Rilmenidine hemifumarate [54187-04-1]; Up 200; 8.4uM; MCF7; HT_HG-U133A	CIDEB STRN3 RPS6KA2 ALS2CL PRX AGT ZC3H7B EDRF1	4.61e-05	200	146	8	5532_UP
Drug	AC1L1IHP	STRN3 MYL2 RPS6KA5 ACO1 RPS6KA2 RPS6KA3 APOB PTPRD PIK3C2G PIK3C3 AGT CEP131 MYL10 RASAL1 CDK2	7.10e-05	728	146	15	CID000004584
Drug	calmidazolium chloride	MYL2 TCN1 TRPC5 AGT MYL10 ATP2B2 ATP2B4	7.95e-05	160	146	7	CID000002531
Drug	isoflurane	CACNA1S RPS6KA3 LDHAL6B RYR1 AGT ALAS2 DMD ATP2B2 ATP2B4	8.19e-05	279	146	9	CID000003763
Drug	caged ATP	MYL2 CHD1L MYL10 ATP2B2 ATP2B4	8.76e-05	70	146	5	CID000123806
Drug	Ovta	RPS6KA5 RPS6KA2 RPS6KA3	8.93e-05	14	146	3	CID003081047
Drug	AD 288	RPS6KA5 RPS6KA2 RPS6KA3	8.93e-05	14	146	3	CID000073553
Drug	mag-fura-2	CACNA1S RYR1 ATP2B2 ATP2B4	9.09e-05	37	146	4	CID000123839
Drug	NSC-683864	ERCC3 RPS6KA5 RPS6KA2 RPS6KA3 PIK3C2G PIK3C3 CDK2	1.04e-04	167	146	7	CID000148191
Drug	Tetracycline	CIDEB COX19 AMACR RPS6KA2 APOB DBI RRM2 ABCB4 JAK1 ATG4B PIK3C2G AGT MMP2 MYL10	1.05e-04	668	146	14	ctd:D013752
Drug	orthovanadate	ENPP6 RYR1 ABCB4 JAK1 PTPRD PIK3C2G PIK3C3 AIFM1 SLC2A12 ATP2B2 ATP2B4	1.19e-04	435	146	11	CID000061672
Drug	glufosinate	ACO1 PDLIM5 RYR1 SERPINI2 LRP1	1.30e-04	76	146	5	CID000004794
Drug	R165481	RPS6KA5 RPS6KA2 RPS6KA3	1.36e-04	16	146	3	CID005459348
Drug	carbachol	CACNA1S MYL2 RPS6KA5 RPS6KA2 RPS6KA3 TRPC5 RYR1 PIK3C2G PIK3C3 AGT MMP2 MYL10 ATP2B2 ATP2B4	1.42e-04	688	146	14	CID000002551
Drug	hemicholinium-3	RANBP2 SLC6A11 AGT VPS13A SLC6A5	1.47e-04	78	146	5	CID000003585
Drug	linopirdine	RPS6KA2 RPS6KA3 ATP2B2 ATP2B4	1.65e-04	43	146	4	CID000003932
Drug	Succimer	STRN3 ATRX RPS6KA5 RPS6KA2 TRPC5 IKZF1 KLF4 ZEB2 PDLIM5 ZNF518A DDX46 NRXN3 CADPS AHNAK AGT ASPH LRP1 IFI44L MGA DNAJC3	1.70e-04	1264	146	20	ctd:D004113
Drug	Sirolimus	RPS6KA2 RPS6KA3 PABPC1 RYR1 SIRT2 ATG4B AIFM1 AGT BUB1 MMP2 CDK2	1.79e-04	456	146	11	ctd:D020123
Drug	Pizotifen malate [5189-11-7]; Up 200; 9.4uM; PC3; HT_HG-U133A	RYR1 ZNF3 PTPRR BUB1 ASTN1 DNAJC3 KDM4B	1.96e-04	185	146	7	5072_UP
Drug	Lasalocid sodium salt [25999-20-6]; Up 200; 6.6uM; PC3; HT_HG-U133A	KLF4 PARP6 NRXN3 PTPRD FAM210B LRP1 DNAJC3	1.96e-04	185	146	7	6639_UP
Drug	mercury	CIDEB CACNA1S LDHAL6B ZKSCAN7 RYR1 PIK3C2G PIK3C3 AGT BUB1 SENP6 ATP2B2 ATP2B4	2.01e-04	542	146	12	CID000023931
Drug	Prochlorperazine dimaleate [84-02-6]; Down 200; 6.6uM; MCF7; HT_HG-U133A	STRN3 ITGB4 PDLIM5 RFTN1 BUB1 ASPH CDK2	2.02e-04	186	146	7	5010_DN
Drug	XeC compound	CACNA1S TRPC5 RYR1 ATP2B2 ATP2B4	2.08e-04	84	146	5	CID000005701
Drug	Nifuroxazide [965-52-6]; Down 200; 14.6uM; MCF7; HT_HG-U133A	ATRX SPN RPS6KA2 PDLIM5 ARRB1 VPS13A CDK2	2.16e-04	188	146	7	4835_DN
Drug	wortmannin; Up 200; 0.01uM; MCF7; HT_HG-U133A_EA	ATRX RPS6KA5 TAF1C PDLIM5 ARRB1 BUB1 ASPH	2.23e-04	189	146	7	911_UP
Drug	Clioquinol [130-26-7]; Up 200; 13uM; PC3; HT_HG-U133A	PTBP3 TAF1C HKDC1 KLF4 IFI44L MYL10 RASAL1	2.31e-04	190	146	7	4663_UP
Drug	GSK-3beta Inhibitor VIII; Up 200; 10uM; PC3; HT_HG-U133A	SCLY KLF4 ASPH SENP6 CEP131 MGA EDRF1	2.31e-04	190	146	7	7070_UP
Drug	5707885; Down 200; 50uM; PC3; HT_HG-U133A	MON2 ZNF3 ARRB1 PTPRD BUB1 IFI44L CDK2	2.38e-04	191	146	7	6390_DN
Drug	Terfenadine [50679-08-8]; Down 200; 8.4uM; MCF7; HT_HG-U133A	STRN3 EMSY ZNF3 FAM210B VPS13A ATP2B4 EDRF1	2.38e-04	191	146	7	2227_DN
Drug	Rapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A	STRN3 ATRX SCLY FAM210B ASPH EDRF1 BAHCC1	2.38e-04	191	146	7	5204_DN
Drug	Rapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A	CIDEB DCHS2 TCN1 RPS6KA5 RYR1 ZNF3 NRXN3	2.46e-04	192	146	7	5567_UP
Drug	everolimus	ERCC3 RPS6KA5 RPS6KA2 RPS6KA3 PIK3C2G PIK3C3	2.49e-04	136	146	6	CID006442177
Drug	Fenoprofen calcium salt dihydrate [53746-45-5]; Down 200; 7.2uM; MCF7; HT_HG-U133A	PTBP3 ADNP2 KLF4 VPS13A IFT122 ZC3H7B DNAJC3	2.54e-04	193	146	7	3412_DN
Drug	ICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A	SPN IKZF1 ITGB4 PRX NRXN3 VPS13A RASAL1	2.54e-04	193	146	7	7490_UP
Drug	Hydrastinine hydrochloride [4884-68-8]; Up 200; 16.4uM; MCF7; HT_HG-U133A	APOB SLC35G2 RYR1 BUB1 ASPH MYL10 KDM4B	2.54e-04	193	146	7	2283_UP
Drug	dihydropyridine	CACNA1S MYL2 RYR1 AGT DMD ATP2B2 ATP2B4	2.54e-04	193	146	7	CID000104822
Drug	creatine	HK2 LDHAL6B RYR1 SLC6A11 SLC6A5 IFT122 DMD	2.54e-04	193	146	7	CID000000586
Drug	aspirin, USP; Down 200; 100uM; MCF7; HT_HG-U133A	PTBP3 CHD1L PDLIM5 RFTN1 BUB1 CEP131 CDK2	2.54e-04	193	146	7	6964_DN
Drug	Prostaglandin E1; Down 200; 10uM; PC3; HT_HG-U133A	ATRX RPS6KA2 KLF4 PDLIM5 BUB1 ASPH BAHCC1	2.62e-04	194	146	7	6555_DN
Drug	Tenoxicam [59804-37-4]; Up 200; 11.8uM; MCF7; HT_HG-U133A	PTBP3 DCHS2 SPN SLC35G2 NRIP3 DMD MYL10	2.62e-04	194	146	7	4182_UP
Drug	Guaifenesin [93-14-1]; Up 200; 20.2uM; MCF7; HT_HG-U133A	SPN RPS6KA2 IKZF1 EMSY ATP2B4 KDM4B CDH18	2.62e-04	194	146	7	4371_UP
Drug	Fludrocortisone acetate [514-36-3]; Up 200; 9.4uM; PC3; HT_HG-U133A	MON2 DCHS2 SCLY KLF4 ZNF3 PARP6 RIMS1	2.62e-04	194	146	7	3785_UP
Drug	Carteolol hydrochloride [51781-21-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A	TRPC5 CHD1L ITGB4 ZNF3 ARRB1 ASPH CDK2	2.62e-04	194	146	7	4176_DN
Drug	Ampyrone [83-07-8]; Down 200; 19.6uM; MCF7; HT_HG-U133A	CIDEB RPS6KA5 SPN ALS2CL VPS13A SENP6 ATP2B4	2.70e-04	195	146	7	6845_DN
Drug	Disopyramide [3737-09-5]; Down 200; 11.8uM; MCF7; HT_HG-U133A	PTBP3 ATRX RPS6KA5 CHD1L PDLIM5 BUB1 CDK2	2.70e-04	195	146	7	7035_DN
Drug	Suxibuzone [27470-51-5]; Up 200; 9.2uM; MCF7; HT_HG-U133A	MON2 RPS6KA2 IKZF1 PDLIM5 PRX RIMS1 ZC3H7B	2.70e-04	195	146	7	6065_UP
Drug	Dehydrocholic acid [81-23-2]; Down 200; 9.6uM; MCF7; HT_HG-U133A	PTBP3 RPS6KA5 RFTN1 FAM210B SENP6 EDRF1 KDM4B	2.70e-04	195	146	7	1523_DN
Drug	oxaprozin; Down 200; 300uM; MCF7; HT_HG-U133A_EA	STRN3 ARRB1 FAM210B PDCD11 ZC3H7B KDM4B BAHCC1	2.70e-04	195	146	7	863_DN
Drug	radicicol; Up 200; 0.1uM; MCF7; HG-U133A	PTBP3 ABHD3 PDLIM5 AGT VPS13A ATP2B4 KDM4B	2.70e-04	195	146	7	325_UP
Drug	Progesterone [57-83-0]; Down 200; 12.8uM; MCF7; HT_HG-U133A	DOC2A STRN3 ATRX SCLY ASPH VPS13A MMP2	2.70e-04	195	146	7	3287_DN
Drug	Suprofen [40828-46-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A	IKZF1 SLC35G2 ITGB4 ZNF3 ARRB1 ASPH ATP2B4	2.70e-04	195	146	7	4123_UP
Drug	Magnetite Nanoparticles	STRN3 ATRX RPS6KA5 RPS6KA2 IKZF1 KLF4 ZEB2 PDLIM5 ZNF518A DDX46 NRXN3 CADPS AHNAK AGT ASPH LRP1 IFI44L MMP2 MGA DNAJC3	2.71e-04	1310	146	20	ctd:D058185
Drug	Trp-Trp	KNTC1 TRPC5 PDLIM5 RYR1	2.75e-04	49	146	4	CID000088656
Drug	Kaempferol [520-18-3]; Up 200; 14uM; MCF7; HT_HG-U133A	AMACR RPS6KA2 IKZF1 KLF4 RFTN1 BUB1 SSX3	2.79e-04	196	146	7	3579_UP
Drug	Sulpiride [15676-16-1]; Up 200; 11.8uM; HL60; HG-U133A	ABHD3 CHD1L RGS1 AHNAK IFT122 MYL10 DNAJC3	2.79e-04	196	146	7	1967_UP
Drug	Nomifensine maleate [32795-47-4]; Down 200; 11.2uM; PC3; HT_HG-U133A	ATRX TCN1 SCLY SIRT2 BUB1 SENP6 KDM2A	2.79e-04	196	146	7	5863_DN
Drug	Tolazamide [1156-19-0]; Down 200; 12.8uM; HL60; HT_HG-U133A	SPN IKZF1 ALS2CL PDLIM5 SERPINI2 FAM210B BUB1	2.79e-04	196	146	7	2482_DN
Drug	Dipivefrin hydrochloride [64019-93-8]; Down 200; 10.4uM; MCF7; HT_HG-U133A	MON2 CIDEB PTBP3 ITGB4 ZC3H7B EDRF1 RASAL1	2.79e-04	196	146	7	6766_DN
Drug	Epirizole [18694-40-1]; Up 200; 17uM; PC3; HT_HG-U133A	RPS6KA2 LRP1 SENP6 MMP2 ZC3H7B MYL10 SSX3	2.87e-04	197	146	7	7292_UP
Drug	Gemfibrozil [25812-30-0]; Up 200; 16uM; PC3; HT_HG-U133A	PRX ZNF3 PARP6 LRP1 ZC3H7B RASAL1 KDM4B	2.87e-04	197	146	7	5069_UP
Drug	Viomycin sulfate [37883-00-4]; Down 200; 5.2uM; HL60; HT_HG-U133A	STRN3 TAF1C IKZF1 ABCB4 AHNAK ZC3H7B MYL10	2.87e-04	197	146	7	2979_DN
Drug	Spaglumic acid [4910-46-7]; Down 200; 13.2uM; MCF7; HT_HG-U133A	PTBP3 STRN3 SPN EMSY ASPH EDRF1 KDM4B	2.87e-04	197	146	7	7465_DN
Drug	Mefexamide hydrochloride [3413-64-7]; Down 200; 12.6uM; MCF7; HT_HG-U133A	PTBP3 STRN3 SCLY TESK2 ASPH IFT122 EDRF1	2.87e-04	197	146	7	7478_DN
Drug	sodium 4-phenylbutyrate; Up 200; 1000uM; MCF7; HG-U133A	DOC2A RPS6KA5 ABHD3 APOB RFTN1 ASPH MYL10	2.87e-04	197	146	7	407_UP
Drug	Deltaline [6836-11-9]; Down 200; 7.8uM; HL60; HT_HG-U133A	PTBP3 SPN IKZF1 AHNAK KDM2A CEP131 MYL10	2.87e-04	197	146	7	2171_DN
Drug	valdecoxib; Up 200; 10uM; PC3; HT_HG-U133A	ITGB4 SLC6A11 ARRB1 PTPRD FAM210B EDRF1 KDM4B	2.87e-04	197	146	7	6378_UP
Drug	Isoconazole [27523-40-6]; Down 200; 9.6uM; HL60; HG-U133A	ABHD3 ALS2CL RGS1 VPS13A KDM2A ZC3H7B ATP2B4	2.87e-04	197	146	7	1372_DN
Drug	Galanthamine hydrobromide [1953-04-4]; Down 200; 10.8uM; HL60; HT_HG-U133A	MON2 PTBP3 STRN3 SPN ALS2CL ITGB4 ASPH	2.87e-04	197	146	7	2131_DN
Drug	Monocrotaline [315-22-0]; Down 200; 12.2uM; MCF7; HT_HG-U133A	MON2 SPN EMSY PDLIM5 RFTN1 ARRB1 ZC3H7B	2.87e-04	197	146	7	6771_DN
Drug	Diazoxide [364-98-7]; Up 200; 17.4uM; MCF7; HT_HG-U133A	PTBP3 STRN3 IKZF1 ASPH SENP6 SSX3 ATP2B4	2.87e-04	197	146	7	7168_UP
Drug	novobiocin sodium, USP; Up 200; 100uM; MCF7; HG-U133A	TCN1 SPN IKZF1 PRX DMD MYL10 CDH18	2.87e-04	197	146	7	576_UP
Drug	beta- Belladonnine dichloroethylate [191355-47-2]; Down 200; 6uM; HL60; HT_HG-U133A	DOC2A STRN3 SPN TAF1C AHNAK KDM2A SSX3	2.96e-04	198	146	7	2164_DN
Drug	Nitrarine dihydrochloride [20069-05-0]; Down 200; 10.6uM; HL60; HT_HG-U133A	PTBP3 STRN3 TAF1C IKZF1 ARRB1 BUB1 MYL10	2.96e-04	198	146	7	2188_DN
Drug	Kynurenine, 3-hydroxy (R,S) [2147-61-7]; Down 200; 17.8uM; PC3; HT_HG-U133A	STRN3 SPN IKZF1 SIRT2 PTPRR LRP1 DNAJC3	2.96e-04	198	146	7	4681_DN
Drug	Meticrane [1084-65-7]; Up 200; 14.6uM; PC3; HT_HG-U133A	STRN3 SLC35G2 TESK2 LRP1 SENP6 MYL10 EDRF1	2.96e-04	198	146	7	7282_UP
Drug	2-propylpentanoic acid; Down 200; 500uM; PC3; HT_HG-U133A	PDLIM5 FAM210B BUB1 ASPH MMP2 MYL10 EDRF1	2.96e-04	198	146	7	4464_DN
Disease	Rare disease with malignant hyperthermia	CACNA1S SELENON RYR1	4.83e-07	4	147	3	cv:C5681128
Disease	Malignant hyperthermia, susceptibility to	CACNA1S RYR1	2.47e-05	2	147	2	cv:C5437603
Disease	Malignant hyperthermia	CACNA1S RYR1	2.47e-05	2	147	2	cv:C5779784
Disease	Malignant hyperpyrexia due to anesthesia	CACNA1S RYR1	2.47e-05	2	147	2	C0024591
Disease	Multiminicore myopathy	SELENON RYR1	2.47e-05	2	147	2	cv:C0270962
Disease	Congenital myopathy (disorder)	CACNA1S SELENON RYR1	2.58e-05	12	147	3	C0270960
Disease	Colorectal Carcinoma	AMACR APOB RRM2 ZEB2 ABCB4 PTPRD BUB1 VPS13A LRP1 KDM2A MMP2 DMD EDRF1	5.27e-05	702	147	13	C0009402
Disease	malignant hyperthermia (is_implicated_in)	CACNA1S RYR1	7.37e-05	3	147	2	DOID:8545 (is_implicated_in)
Disease	dilated cardiomyopathy 1H (is_marker_for)	TRPC5 AIFM1	7.37e-05	3	147	2	DOID:0110429 (is_marker_for)
Disease	Congenital Fiber Type Disproportion	MYL2 SELENON RYR1	9.36e-05	18	147	3	C0546264
Disease	Coffin-Lowry syndrome (implicated_via_orthology)	RPS6KA2 RPS6KA3	1.47e-04	4	147	2	DOID:3783 (implicated_via_orthology)
Disease	hypertrophic cardiomyopathy 10 (implicated_via_orthology)	MYL2 MYL10	2.44e-04	5	147	2	DOID:0110316 (implicated_via_orthology)
Disease	hyperinsulinemic hypoglycemia (implicated_via_orthology)	HK2 HKDC1	2.44e-04	5	147	2	DOID:13317 (implicated_via_orthology)
Disease	Neoplasm Invasiveness	ACO1 RPS6KA3 ZEB2 AHNAK MMP2 DMD	3.31e-04	184	147	6	C0027626
Disease	colorectal cancer (is_implicated_in)	IKZF1 JAK1 BUB1 TRPV3 KDM4B	3.58e-04	121	147	5	DOID:9256 (is_implicated_in)
Disease	Congenital myopathy with fiber type disproportion	SELENON RYR1	3.65e-04	6	147	2	cv:C0546264
Disease	Hailey-Hailey disease (implicated_via_orthology)	ATP2B2 ATP2B4	3.65e-04	6	147	2	DOID:0050429 (implicated_via_orthology)
Disease	Hereditary, Type VII, Motor and Sensory Neuropathy	AMACR PRX	3.65e-04	6	147	2	C0019816
Disease	Hereditary Motor and Sensory Neuropathies	AMACR PRX	3.65e-04	6	147	2	C0027888
Disease	Neointima Formation	AGT MMP2	3.65e-04	6	147	2	C2936381
Disease	Neointima	AGT MMP2	3.65e-04	6	147	2	C2936380
Disease	progressive supranuclear palsy	PIK3C2G ATP2B2 ATP2B4	4.92e-04	31	147	3	MONDO_0019037
Disease	Colorectal Neoplasms	AMACR RRM2 ABCB4 PTPRD BUB1 KDM2A MMP2	4.96e-04	277	147	7	C0009404
Disease	Shwachman-Diamond syndrome (implicated_via_orthology)	SRP54 SERPINI2	5.09e-04	7	147	2	DOID:0060479 (implicated_via_orthology)
Disease	Dejerine-Sottas Disease (disorder)	AMACR PRX	5.09e-04	7	147	2	C0011195
Disease	cysteine-rich with EGF-like domain protein 1 measurement	SLC6A11 ATP2B2 ATP2B4	5.40e-04	32	147	3	EFO_0021870
Disease	Muscular Dystrophy	SELENON DMD	6.77e-04	8	147	2	C0026850
Disease	Duchenne muscular dystrophy (implicated_via_orthology)	CACNA1S SLC6A5 DMD	7.67e-04	36	147	3	DOID:11723 (implicated_via_orthology)
Disease	maturity-onset diabetes of the young (implicated_via_orthology)	HK2 HKDC1	1.08e-03	10	147	2	DOID:0050524 (implicated_via_orthology)
Disease	temporomandibular joint disorder	DMD BAHCC1	1.08e-03	10	147	2	EFO_0005279
Disease	Tumoral calcinosis	SPN MMP2 DMD	1.21e-03	42	147	3	C0263628
Disease	Calcinosis	SPN MMP2 DMD	1.21e-03	42	147	3	C0006663
Disease	Microcalcification	SPN MMP2 DMD	1.21e-03	42	147	3	C0521174
Disease	fear of severe pain measurement	PTPRR MYOCD	1.32e-03	11	147	2	EFO_0008338
Disease	Alzheimer disease, APOE carrier status	RPS6KA2 FAM135B FAM210B KDM4B	1.49e-03	98	147	4	EFO_0007659, MONDO_0004975
Disease	melanoma	ERCC3 SLC35G2 SLC6A11 HOXD12 KDM4B CDK2	1.56e-03	248	147	6	C0025202
Disease	IgG galactosylation measurement	IKZF1 CEP131	1.57e-03	12	147	2	EFO_0008425
Disease	Congenital muscular dystrophy	SELENON RYR1	1.57e-03	12	147	2	cv:C0699743
Disease	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	IKZF1 MGA	1.57e-03	12	147	2	C0023485
Disease	focal segmental glomerulosclerosis (biomarker_via_orthology)	AGT MMP2	1.57e-03	12	147	2	DOID:1312 (biomarker_via_orthology)
Disease	Liver Cirrhosis	ABCB4 ARRB1 AGT MMP2	1.78e-03	103	147	4	C0023890
Disease	Autosomal Dominant Myotubular Myopathy	SELENON RYR1	1.85e-03	13	147	2	C3661489
Disease	Centronuclear myopathy	SELENON RYR1	1.85e-03	13	147	2	C0175709
Disease	X-linked centronuclear myopathy	SELENON RYR1	1.85e-03	13	147	2	C0410203
Disease	Myopathy, Centronuclear, 1	SELENON RYR1	1.85e-03	13	147	2	C4551952
Disease	skin melanoma (is_marker_for)	AGT MMP2	1.85e-03	13	147	2	DOID:8923 (is_marker_for)
Disease	Congenital Structural Myopathy	SELENON RYR1	1.85e-03	13	147	2	C0752282
Disease	Fibrosis, Liver	ABCB4 ARRB1 AGT MMP2	1.91e-03	105	147	4	C0239946
Disease	diabetic retinopathy (is_implicated_in)	APOB AGT MMP2	2.00e-03	50	147	3	DOID:8947 (is_implicated_in)
Disease	Myopathy, Centronuclear, Autosomal Dominant	SELENON RYR1	2.16e-03	14	147	2	C1834558
Disease	Tubular Aggregate Myopathy	SELENON RYR1	2.16e-03	14	147	2	C0410207
Disease	Antihypertensive use measurement	RPS6KA3 INO80 AGT ATP2B2 ATP2B4 KDM4B	2.18e-03	265	147	6	EFO_0009927
Disease	Alcoholic Intoxication, Chronic	ANKK1 NRXN3 TESK2 ASTN1 MMP2 CDH18	2.31e-03	268	147	6	C0001973
Disease	Glioblastoma Multiforme	ATRX RPS6KA3 MMP2 CDK2	2.34e-03	111	147	4	C1621958
Disease	Autosomal Recessive Centronuclear Myopathy	SELENON RYR1	2.48e-03	15	147	2	C3645536
Disease	amenorrhea, response to antineoplastic agent	APOB RIMS1	2.48e-03	15	147	2	EFO_0010269, GO_0097327
Disease	Necrosis	AIFM1 AGT DMD	2.63e-03	55	147	3	C0027540
Disease	hyperglycemia (implicated_via_orthology)	HK2 HKDC1	3.19e-03	17	147	2	DOID:4195 (implicated_via_orthology)
Disease	APOE carrier status, dementia	RPS6KA2 FAM135B FAM210B	3.70e-03	62	147	3	EFO_0007659, MONDO_0001627
Disease	inosine measurement	RPS6KA2 DMD	3.99e-03	19	147	2	EFO_0010503
Disease	Cardiomyopathies	MYL2 AGT MYOCD DMD	4.13e-03	130	147	4	C0878544
Disease	body weight	KNTC1 PTBP3 RPS6KA5 HECTD4 CHD1L NRXN3 PTPRR CADPS SENP6 KDM2A DMD MGA ATP2B4 KDM4B	4.27e-03	1261	147	14	EFO_0004338
Disease	myocardial infarction (implicated_via_orthology)	RYR1 AGT MMP2	4.41e-03	66	147	3	DOID:5844 (implicated_via_orthology)
Disease	Fetal Growth Retardation	AGT MMP2	4.42e-03	20	147	2	C0015934
Disease	radiation-induced disorder	DCHS2 PDLIM5 PTPRD	4.60e-03	67	147	3	EFO_0009565
Disease	Schizophrenia	ANKK1 AMACR ADNP2 ALS2CL PDLIM5 SLC6A11 NRXN3 NRXN2 PIK3C3 SLC6A5 LRP1	4.81e-03	883	147	11	C0036341
Disease	fumarate measurement	RPS6KA2 RFTN1	4.86e-03	21	147	2	EFO_0010480
Disease	Infiltrating duct carcinoma of female breast	ANKK1 TESK2	4.86e-03	21	147	2	C3165106

Protein segments in the cluster

Peptide	Gene	Start	Entry
SNPSVMLGAGLLAKK	ACO1	441	P21399
DLTLMGKGKVTFPNG	ALS2CL	536	Q60I27
ALLMGDKDFSPKLGR	BAHCC1	2256	Q9P281
GKKMLDITPGCKSLF	CFAP54	1231	Q96N23
MSASAVFILDVKGKP	AP1M2	1	Q9Y6Q5
GTIKLKVFLSGMPEL	AP1M2	196	Q9Y6Q5
DLGQSIDMKLFPKGT	BUB1	946	O43683
EKGNMGKILPEYLSN	AIFM1	336	O95831
KGLGLKSDELPNQMS	AMACR	246	Q9UHK6
RKQGIMSFLEGKEPS	ANKK1	736	Q8NFD2
EMNRLFSGKGDITKP	FBXW10	236	Q5XX13
GKIGSKTPLMAAATF	ABHD3	231	Q8WU67
MKIPKFTFSGRELVG	AHNAK	5661	Q09666
LGNIFEKLGICSMPK	AADACL4	56	Q5VUY2
GLAVMDKAKGLFLPE	ASPH	601	Q12797
ALKEKGQGPMFLDAD	DMD	896	P11532
FLAMGKSKAALPDLT	DNAJC3	81	Q13217
MGDKGTRVFKKASPN	ARRB1	1	P49407
PALKKADVGFAMGIA	ATP2B2	826	Q01814
PALKKADVGFAMGIA	ATP2B4	791	P23634
KSGMDLTPGSDNAKL	ASTN1	281	O14525
VKKLSLLGGALPMFE	ATG4B	336	Q9Y4P1
KPSVLLGFDMSELKN	ADNP2	1106	Q6IQ32
QGKMKGFSLLAEPQE	AGT	276	P01019
KMQKFFGLPQTGDLD	MMP2	76	P08253
VGKNDFLGMVEFSPK	RASAL1	206	O95294
EISKAPKSGFEGMFI	RANBP2	1766	P49792
DGEPMKGVKFLLFSS	NOMO3	226	P69849
EPLSGKMEIFTLFNK	RFTN1	271	Q14699
GMFFSANPKELKGTT	RGS1	16	Q08116
KMENGQITPDGFLSK	INTS6L	681	Q5JSJ4
GIKLIMEFLPSGSLK	JAK1	951	P23458
PMGKNISIIFKAGDD	PIK3C2G	911	O75747
SFPALGTGNMEIKKE	PARP9	426	Q8IXQ6
RMVISGGNFKPDTLK	INO80	1246	Q9ULG1
PRFLVMKGQEGAASK	SLC2A12	221	Q8TD20
FGKFGPALSVKVMTD	PABPC1	211	P11940
VFLTMFGEKLKGADP	MYL2	81	P10916
KSIPFGMKSAVERGL	ANKAR	496	Q7Z5J8
SMPVSKGGEFKLQKL	CADPS	356	Q9ULU8
DGEPMKGVKFLLFSS	NOMO2	226	Q5JPE7
MGKFVLKASLSAPGS	KLF4	226	O43474
KDFLGSGDPKETKML	IFT122	736	Q9HBG6
EFLPKKISGDMRGIQ	MGA	2741	Q8IWI9
LAMEELKSGSGPSLK	SPN	356	P16150
GPEGLEKQMALFLDK	EDRF1	646	Q3B7T1
MLTGTLPFQGKDRKE	RPS6KA3	261	P51812
KGIALDPAMGKVFFT	LRP1	326	Q07954
SVKDGKNGKSLPFML	IFI44L	246	Q53G44
VPVGGMADLNFKISK	HECTD2	716	Q5U5R9
MFTSKLKEGSLGINP	FSIP2	3166	Q5CZC0
IDMGSLNPGKQLFEK	HK2	281	P52789
KLMLQEPLEKLGFGD	COX19	66	Q49B96
KLKGETMDLQHGSPF	LDHAL6B	106	Q9BYZ2
KLGGFPISLAMATKL	MINDY4B	91	A8MYZ0
FMKILGKGKSESELP	OR2M2	301	Q96R28
SGVDMPAILLKLGFK	FAM210B	121	Q96KR6
EGDPKMKLQGDLSFR	NRXN2	471	Q9P2S2
VQAMPGFKGLILDLK	NRXN3	166	Q9Y4C0
DGEPMKGVKFLLFSS	NOMO1	226	Q15155
AGEGQAPSTFSKLKM	KDM4B	591	O94953
ELFCSSPKEGMIKGL	KNTC1	1936	P50748
MSPVFGLLVDKTGKN	MFSD1	316	Q9H3U5
GLLTVDPNKRLKMSG	RPS6KA5	666	O75582
VFLTMFGEKLKGTDP	MYL10	141	Q9BUA6
IGQKFPKSMEISLSG	AP5M1	391	Q9H0R1
GKDFNMPLTISSLKD	PDLIM5	21	Q96HC4
MPLTISSLKDGGKAA	PDLIM5	26	Q96HC4
SSMPQKFLGDKGLSD	IKZF1	276	Q13422
FLMGCGTKEPKITQL	MON2	71	Q7Z3U7
TPKVMVGFLTGDKFI	OR5B12	76	Q96R08
PFRLGTGANMEKVVK	HECTD4	1556	Q9Y4D8
LKPSFSDGLKMDAGI	ITGB4	436	P16144
PFMLSELQDGKSKIV	ALAS2	71	P22557
PLGKMSDVTLLKIGS	MYOCD	816	Q8IZQ8
LSGKKDGLVPMFINT	MAN1B1	431	Q9UKM7
FGKFGPALSVKVMTD	PABPC3	211	Q9H361
MKLPQKFDTLVGERG	ABCB4	516	P21439
SGKEKAFIATQGPMI	PTPRR	456	Q15256
LSDGKFFKMNPNTGE	DCHS2	1231	Q6V1P9
TTMPKDSGALLGLKV	RIMS1	606	Q86UR5
PFGGKSSRDLKMLET	APOB	1301	P04114
EKKGLTMRFNIPTGT	ATRX	2281	P46100
IMATLGFGDSPKAEK	FBF1	211	Q8TES7
TDFSSQKGVKGLPLM	GRHL2	376	Q6ISB3
LIFKNSDGLGIKMPD	KDM2A	76	Q9Y2K7
LRAKGLKPMDFNGLA	DOC2A	111	Q14183
PMSSKGAGLDVKALR	CACNA1S	151	Q13698
KMKDLSLGGVLLFPV	CHD1L	771	Q86WJ1
PDGMKDLDAIKLFVG	CELF5	36	Q8N6W0
GFKDDTKGPLNLNMT	HOXD12	161	P35452
NTERPGMLDFTGKAK	DBI	41	P07108
LGPFKDATMLKIIVG	CDH18	361	Q13634
ETKFPLSKGLEMGLE	EFHB	61	Q8N7U6
PKKALATSMLTGEAG	EMSY	1171	Q7Z589
RKLSKTGVPDGIMQF	ERCC3	141	P19447
LPGGKLDFLMSEKNQ	FAM135B	1166	Q49AJ0
AKTGSGKTIAFLLPM	DDX46	416	Q7L014
DLKKFMDASALTGIP	CDK2	86	P24941
KSFDIGVNKDSLMPL	ENPP6	101	Q6UWR7
MKSGPEIVKAGLRSF	RYR1	3081	P21817
TDFLMLFEGSPSGKK	CEP131	96	Q9UPN4
FPIIQDSMLKGKLGV	PARP6	186	Q2NL67
KPAFIGKTNLDGMIT	PTPRD	1111	P23468
LDGLKKLGSSKDMQP	NRIP3	46	Q9NQ35
MGSGPKESALKALNS	SMG8	871	Q8ND04
KYGTELNQGDLKMPT	STRN3	136	Q13033
LPASGLDIFGDLKKM	SEC11C	11	Q9BY50
KTQPFISKLLGMGDI	SRP54	286	P61011
KNMIDPLGTSSLGLK	SLC6A5	771	Q9Y345
LNPGKQLFEKMISGL	HKDC1	286	Q2TB90
ATKNRVGFLKEMGTP	RPL7L1	226	Q6DKI1
PLGKLMLENFKLEGA	TAF1C	121	Q15572
GNFMEENPKKGLLSE	SLC35G2	46	Q8TBE7
LSDKSLSILKMVGPG	PIRT	81	P0C851
LMPAQLFFKTEDGGK	PIK3C3	616	Q8NEB9
EAMTKLGFKAILPSF	SSX3	56	Q99909
NKEKAGQSDPFLGMI	SIRT2	286	Q8IXJ6
MGKEGNYDLKLAELP	HERC2P3	646	Q9BVR0
DFFPKDDKGNMISGK	AKR1B15	121	C9JRZ8
SMSCDFQGLGPKKVL	CIDEB	161	Q9UHD4
KAKESGMALPQGRLT	ZNF610	11	Q8N9Z0
DLTGIFMHGKIPTLK	PRPF8	1556	Q6P2Q9
GLSGLAPKAIMSDKF	PDCD11	751	Q14690
SLAKMIGGKPQDIIF	SCLY	81	Q96I15
EKPLNGIGMSKSSLR	ZNF3	421	P17036
KKATPRMIGLTVGFD	VPS13A	1466	Q96RL7
VPDLSSDLGMNIFKK	UNC80	431	Q8N2C7
MGFTIDIKSFLKPGE	PSPC1	61	Q8WXF1
LKKRGLMPGLTFSNE	RRM2	246	P31350
LKMPSFGLARGKEAE	PRX	1061	Q9BXM0
LPETMTKSKDGFLGV	SELENON	166	Q9NZV5
MSLGTKGLKVNLFPG	TNKS1BP1	1636	Q9C0C2
LPALMGKTFLDINKD	TCN1	291	P20061
MTAEKALPLGNGKAA	SLC6A11	1	P48066
LMEKELPGFLQSGKD	S100P	36	P25815
ESFKTLKGNPIGLNM	SENP6	96	Q9GZR1
KIKDMFSGEEFGPLT	SERPINI2	161	O75830
EKMPRISGFGTLLKT	ZNF518A	876	Q6AHZ1
GKGPSIKQFMDIFSL	NT5DC2	176	Q9H857
PFGKVTNLLMLKGKS	PTBP3	81	O95758
MKGSELTPKQEFFKG	ZKSCAN7	276	Q9P0L1
GLTPLQLAAKMGKAE	TRPV3	341	Q8NET8
GPGMTLQLKLKESFL	SFTA2	21	Q6UW10
SFMGPSLKKLGLLFS	TRPC5	836	Q9UL62
EKKSGLSVRFADMPG	WBP11	301	Q9Y2W2
GKPLSMSEQTGLLKI	ZEB2	376	O60315
QDLMGGKIKFFDLPS	TESK2	406	Q96S53
KGIPQTMAAFGLKDS	VN1R3	61	Q9BXE9
FGLVMDPSKKLAASV	ZC3H7B	321	Q9UGR2
EMLTGSLPFQGKDRK	RPS6KA2	251	Q15349
ILKAKLGMPQFLSGE	RPS6KA2	271	Q15349